TY  - JOUR
AU  - Radojević, Branislava S.
AU  - Jančić, Ivan
AU  - Savić, Miroslav
AU  - Kostić, Vladimir S.
AU  - Dragašević-Mišković, Nataša T.
PY  - 2024
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/5581
AB  - Catechol-O-methyltransferase (COMT) is one of the cardinal enzymes in the degradation
of catecholamines and levodopa. Genetic variants of the COMT gene may affect COMT enzyme
activity. The most examined COMT gene polymorphism is the nonsynonymous single nucleotide
polymorphism (SNP) in exon 4 (Val108/158Met; rs4680). This highly functional polymorphism
is responsible for fourfold variations in enzyme activity and dopamine catabolism. Recent data
suggested that even synonymous SNPs of the COMT gene can lead to changes in enzyme activity.
Genetically determined COMT activity can affect an individual's response to levodopa therapy
and carries the risk of complications from prolonged levodopa use in Parkinson's disease (PD)
patients. Identifying at-risk individuals through genetic susceptibility markers could help to
prevent the development of levodopa-induced complications in PD.
AB  - Katehol-O-metiltransferaza (engl. catechol-O-methyltransferase, COMT) je jedan od
glavnih enzima u razgradnji kateholamina i levodope. Genetske varijante COMT gena mogu
uticati na aktivnost COMT enzima. Polimorfizam COMT gena koji je najviše proučavan je
nesinonimni jednonukleotidni polimorfizam (engl. single nucleotide polymorphism, SNP) u
egzonu 4 (Val108/158Met; rs4680). Ovaj visoko funkcionalni polimorfizam odgovoran je za
četvorostruke varijacije u aktivnosti enzima i katabolizmu dopamina. Nedavni podaci sugerišu da
čak i sinonimni SNP COMT gena mogu da dovedu do promena u aktivnosti enzima. Genetski
određene razlike u COMT aktivnosti mogu uticati na odgovor pojedinca na terapiju levodopom i
nose rizik od komplikacija dugotrajne primene levodope kod pacijenata sa Parkinsonovom
bolešću (PB). Identifikacija osoba u riziku putem markera genetske osetljivosti može pomoći u
prevenciji komplikacija izazvanih levodopom kod PB.
PB  - Beograd : Savez farmaceutskih udruženja Srbije
PB  - Beograd : Univerzitet u Beogradu - Farmaceutski fakultet
T2  - Arhiv za farmaciju
T1  - Association of catechol-O-methyltransferase gene polymorphisms with treatment response and levodopa-induced complications in Parkinson's disease: A summary of current knowledge
T1  - Udruženost polimorfizama gena za katehol-O- metiltransferazu sa terapijskim odgovorom i komplikacijama izazvanim levodopom kod Parkinsonove bolesti: Rezime sadašnjih saznanja
VL  - 74
IS  - 1
SP  - 23
EP  - 37
DO  - 10.5937/arhfarm74-45472
ER  - 

@article{
author = "Radojević, Branislava S. and Jančić, Ivan and Savić, Miroslav and Kostić, Vladimir S. and Dragašević-Mišković, Nataša T.",
year = "2024",
abstract = "Catechol-O-methyltransferase (COMT) is one of the cardinal enzymes in the degradation
of catecholamines and levodopa. Genetic variants of the COMT gene may affect COMT enzyme
activity. The most examined COMT gene polymorphism is the nonsynonymous single nucleotide
polymorphism (SNP) in exon 4 (Val108/158Met; rs4680). This highly functional polymorphism
is responsible for fourfold variations in enzyme activity and dopamine catabolism. Recent data
suggested that even synonymous SNPs of the COMT gene can lead to changes in enzyme activity.
Genetically determined COMT activity can affect an individual's response to levodopa therapy
and carries the risk of complications from prolonged levodopa use in Parkinson's disease (PD)
patients. Identifying at-risk individuals through genetic susceptibility markers could help to
prevent the development of levodopa-induced complications in PD., Katehol-O-metiltransferaza (engl. catechol-O-methyltransferase, COMT) je jedan od
glavnih enzima u razgradnji kateholamina i levodope. Genetske varijante COMT gena mogu
uticati na aktivnost COMT enzima. Polimorfizam COMT gena koji je najviše proučavan je
nesinonimni jednonukleotidni polimorfizam (engl. single nucleotide polymorphism, SNP) u
egzonu 4 (Val108/158Met; rs4680). Ovaj visoko funkcionalni polimorfizam odgovoran je za
četvorostruke varijacije u aktivnosti enzima i katabolizmu dopamina. Nedavni podaci sugerišu da
čak i sinonimni SNP COMT gena mogu da dovedu do promena u aktivnosti enzima. Genetski
određene razlike u COMT aktivnosti mogu uticati na odgovor pojedinca na terapiju levodopom i
nose rizik od komplikacija dugotrajne primene levodope kod pacijenata sa Parkinsonovom
bolešću (PB). Identifikacija osoba u riziku putem markera genetske osetljivosti može pomoći u
prevenciji komplikacija izazvanih levodopom kod PB.",
publisher = "Beograd : Savez farmaceutskih udruženja Srbije, Beograd : Univerzitet u Beogradu - Farmaceutski fakultet",
journal = "Arhiv za farmaciju",
title = "Association of catechol-O-methyltransferase gene polymorphisms with treatment response and levodopa-induced complications in Parkinson's disease: A summary of current knowledge, Udruženost polimorfizama gena za katehol-O- metiltransferazu sa terapijskim odgovorom i komplikacijama izazvanim levodopom kod Parkinsonove bolesti: Rezime sadašnjih saznanja",
volume = "74",
number = "1",
pages = "23-37",
doi = "10.5937/arhfarm74-45472"
}

Radojević, B. S., Jančić, I., Savić, M., Kostić, V. S.,& Dragašević-Mišković, N. T.. (2024). Association of catechol-O-methyltransferase gene polymorphisms with treatment response and levodopa-induced complications in Parkinson's disease: A summary of current knowledge. in Arhiv za farmaciju
Beograd : Savez farmaceutskih udruženja Srbije., 74(1), 23-37.
https://doi.org/10.5937/arhfarm74-45472

Radojević BS, Jančić I, Savić M, Kostić VS, Dragašević-Mišković NT. Association of catechol-O-methyltransferase gene polymorphisms with treatment response and levodopa-induced complications in Parkinson's disease: A summary of current knowledge. in Arhiv za farmaciju. 2024;74(1):23-37.
doi:10.5937/arhfarm74-45472 .

Radojević, Branislava S., Jančić, Ivan, Savić, Miroslav, Kostić, Vladimir S., Dragašević-Mišković, Nataša T., "Association of catechol-O-methyltransferase gene polymorphisms with treatment response and levodopa-induced complications in Parkinson's disease: A summary of current knowledge" in Arhiv za farmaciju, 74, no. 1 (2024):23-37,
https://doi.org/10.5937/arhfarm74-45472 . .

TY  - CONF
AU  - Aranđelović, Jovana
AU  - Kojić, Jana
AU  - Mirković, Kristina
AU  - Jančić, Ivan
AU  - Todorović, Lidija
AU  - Savić, Miroslav
PY  - 2023
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/5520
AB  - Introduction: Impulsivity is an umbrella term that encompasses many subdomains, most of which rely on the decision-making processes. It is reported that in the process of healthy aging, the two dimensions of impulse control, cognition and motivation, are preserved or even improved. On the other hand, the attentive efficiency seems to decrease with age. Therefore, we aimed to investigate the effects of healthy aging on impulsivity in rats and the influence of food deprivation on impulsivity in aged rats as a strategy to enhance motivation. Additionally, we wanted to assess the gene expression for the alpha5 GABAA receptor subunit during aging, which plays a role in cognitive processes. Methodology: The variable-delay-to-signal (VDS) paradigm adapted to a touchscreen environment was used to assess impulsivity and attention in Sprague-Dawley rats at 2, 3, 5, 8, and 14 months of age. After one week of training, animals were tested at different ages in 3-stage testing protocol. Additionally, prior to testing, animals were fed a restricted diet (16 g/animal). The first stage included 20 trials with inter-trial interval of 6s (ITI6si) that reflected motor impulsivity. The second stage, with 60 randomly distributed trials of ITI9s or 15s, was related to delay intolerance, while the final stage (ITI6sf), similar to the first, was related to reflection impulsivity. The strict 3-day restriction diet (24h food deprivation followed by 10g/day/animal and 8g/day/animal) was applied to 14-month-old animals before testing. Gabra5 expression in the hippocampus was determined by qPCR. Results were analyzed by one-way ANOVA with or without repeated measures, followed by Sidak post-hoc test for impulsivity and attention parameters and by t-test for PCR parameters. Results: Animals aged 8 and 14 months had reduced motor impulsivity (p<0.01 for both groups) and delay intolerance (p<0.05 for both groups) and higher number of omissions (p<0.05 for both groups) compared to animals aged 2, 3 and 5 months of age. In addition, half of the animals were unable to successfully complete a task after 14 months. After rigorous food restriction in 14-month-old animals, the level of impulsivity (ITI9s and ITI15s) and attention (number of omissions) returned to the control level (2 and 3 months of age) compared to the performance of 14-month-old animals prior to rigorous food restriction (p<0.05). Further, the peak of reflection impulsivity (ITI6sf) was reached at 5 months compared to all other groups (p<0.01). No changes in Gabra5 expression in hippocampus were detected in 14-month-old compared to 3-month-old animals. Conclusion: From 8 months of age onwards, rats showed reduced impulsivity in the VDS stages where motor impulsivity and delay intolerance were tested, followed by attention deficits. After strict food restriction in 14-month-old animals, delay intolerance and attention were restored, suggesting the prominent role of motivation in controlling these processes, independently of Gabra5 expression levels in the hippocampus. Since the VDS paradigm aims to assess reward-related impulsivity based on cognition and motivation, it is suspected that results related to impaired cognition in older animals in other cognitive tests should be interpreted with caution, and with additional observation of motivation.
PB  - European College of Neuropsychopharmacology (ECNP)
C3  - 36th ECPN congress, 7th -10th October 2023, Barcelona, Spain
T1  - Reward-related impulsivity as a possible surrogate marker of motivation in aging Sprague-Dawley rats
UR  - https://hdl.handle.net/21.15107/rcub_farfar_5520
ER  - 

@conference{
author = "Aranđelović, Jovana and Kojić, Jana and Mirković, Kristina and Jančić, Ivan and Todorović, Lidija and Savić, Miroslav",
year = "2023",
abstract = "Introduction: Impulsivity is an umbrella term that encompasses many subdomains, most of which rely on the decision-making processes. It is reported that in the process of healthy aging, the two dimensions of impulse control, cognition and motivation, are preserved or even improved. On the other hand, the attentive efficiency seems to decrease with age. Therefore, we aimed to investigate the effects of healthy aging on impulsivity in rats and the influence of food deprivation on impulsivity in aged rats as a strategy to enhance motivation. Additionally, we wanted to assess the gene expression for the alpha5 GABAA receptor subunit during aging, which plays a role in cognitive processes. Methodology: The variable-delay-to-signal (VDS) paradigm adapted to a touchscreen environment was used to assess impulsivity and attention in Sprague-Dawley rats at 2, 3, 5, 8, and 14 months of age. After one week of training, animals were tested at different ages in 3-stage testing protocol. Additionally, prior to testing, animals were fed a restricted diet (16 g/animal). The first stage included 20 trials with inter-trial interval of 6s (ITI6si) that reflected motor impulsivity. The second stage, with 60 randomly distributed trials of ITI9s or 15s, was related to delay intolerance, while the final stage (ITI6sf), similar to the first, was related to reflection impulsivity. The strict 3-day restriction diet (24h food deprivation followed by 10g/day/animal and 8g/day/animal) was applied to 14-month-old animals before testing. Gabra5 expression in the hippocampus was determined by qPCR. Results were analyzed by one-way ANOVA with or without repeated measures, followed by Sidak post-hoc test for impulsivity and attention parameters and by t-test for PCR parameters. Results: Animals aged 8 and 14 months had reduced motor impulsivity (p<0.01 for both groups) and delay intolerance (p<0.05 for both groups) and higher number of omissions (p<0.05 for both groups) compared to animals aged 2, 3 and 5 months of age. In addition, half of the animals were unable to successfully complete a task after 14 months. After rigorous food restriction in 14-month-old animals, the level of impulsivity (ITI9s and ITI15s) and attention (number of omissions) returned to the control level (2 and 3 months of age) compared to the performance of 14-month-old animals prior to rigorous food restriction (p<0.05). Further, the peak of reflection impulsivity (ITI6sf) was reached at 5 months compared to all other groups (p<0.01). No changes in Gabra5 expression in hippocampus were detected in 14-month-old compared to 3-month-old animals. Conclusion: From 8 months of age onwards, rats showed reduced impulsivity in the VDS stages where motor impulsivity and delay intolerance were tested, followed by attention deficits. After strict food restriction in 14-month-old animals, delay intolerance and attention were restored, suggesting the prominent role of motivation in controlling these processes, independently of Gabra5 expression levels in the hippocampus. Since the VDS paradigm aims to assess reward-related impulsivity based on cognition and motivation, it is suspected that results related to impaired cognition in older animals in other cognitive tests should be interpreted with caution, and with additional observation of motivation.",
publisher = "European College of Neuropsychopharmacology (ECNP)",
journal = "36th ECPN congress, 7th -10th October 2023, Barcelona, Spain",
title = "Reward-related impulsivity as a possible surrogate marker of motivation in aging Sprague-Dawley rats",
url = "https://hdl.handle.net/21.15107/rcub_farfar_5520"
}

Aranđelović, J., Kojić, J., Mirković, K., Jančić, I., Todorović, L.,& Savić, M.. (2023). Reward-related impulsivity as a possible surrogate marker of motivation in aging Sprague-Dawley rats. in 36th ECPN congress, 7th -10th October 2023, Barcelona, Spain
European College of Neuropsychopharmacology (ECNP)..
https://hdl.handle.net/21.15107/rcub_farfar_5520

Aranđelović J, Kojić J, Mirković K, Jančić I, Todorović L, Savić M. Reward-related impulsivity as a possible surrogate marker of motivation in aging Sprague-Dawley rats. in 36th ECPN congress, 7th -10th October 2023, Barcelona, Spain. 2023;.
https://hdl.handle.net/21.15107/rcub_farfar_5520 .

Aranđelović, Jovana, Kojić, Jana, Mirković, Kristina, Jančić, Ivan, Todorović, Lidija, Savić, Miroslav, "Reward-related impulsivity as a possible surrogate marker of motivation in aging Sprague-Dawley rats" in 36th ECPN congress, 7th -10th October 2023, Barcelona, Spain (2023),
https://hdl.handle.net/21.15107/rcub_farfar_5520 .

TY  - CONF
AU  - Mitrović, Jelena
AU  - Ilić, Tanja
AU  - Jančić, Ivan
AU  - Bufan, Biljana
AU  - Savić, Miroslav
AU  - Savić, Snežana
PY  - 2023
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/5090
AB  - Estimation of endotoxin level in nanocrystal dispersion of DK-I-56-1 intended for parenteral administration
Jelena Mitrović1, Tanja Ilić1, Ivan Jančić2, Biljana Bufan2, Miroslav Savić3, Snežana Savić1
1 Department of Pharmaceutical Technology and Cosmetology, University of Belgrade – Faculty of Pharmacy, Vojvode Stepe 450, 11000 Belgrade, Serbia
2 Department of Microbiology and Immunology, University of Belgrade – Faculty of Pharmacy, Vojvode Stepe 450, 11000 Belgrade, Serbia
3 Department of Pharmacology, University of Belgrade – Faculty of Pharmacy, Vojvode Stepe 450, 11000 Belgrade, Serbia
Estimation of endotoxin level in parenteral formulations is a prerequisite for numerous in vitro tests in preclinical studies and for future clinical development. However, the Limulus amoebocyte lysate (LAL) test in formulations containing nanoparticles could often lead to misinterpretation of results. Therefore, we tested if endotoxins could be detected in nanocrystal dispersions by the commercial gel clot assay kit. Nanocrystals of DK-I-56-1 (7‑methoxy‑2-(4‑methoxy‑d3-phenyl)-2,5-dihydro-3H-pyrazolo[4,3-c]quinolin-3-one) were prepared by wet-ball milling, lyophilized and reconstituted with water for injection prior experiment. Different dilutions of nanocrystal dispersion in LAL reagent water were prepared as well as positive and negative control. Despite difficulties to detect gel clots, they were visible in the sample at dilutions 1:75 and below. According to the protocol, the endotoxin limit was estimated to be 25.00 EU/ml, which corresponds to <12.50 EU/mg of DK-I-56-1. This value relates to the endotoxin limit for diazepam, with the similar dosing regimen as proposed for DK-I-56-1.
C3  - NANOGVA Symposium, October 5th - 6th, 2023, Geneva, Switzerland
T1  - Estimation of endotoxin level in nanocrystal dispersion of DK-I-56-1 intended for parenteral administration
UR  - https://hdl.handle.net/21.15107/rcub_farfar_5090
ER  - 

@conference{
author = "Mitrović, Jelena and Ilić, Tanja and Jančić, Ivan and Bufan, Biljana and Savić, Miroslav and Savić, Snežana",
year = "2023",
abstract = "Estimation of endotoxin level in nanocrystal dispersion of DK-I-56-1 intended for parenteral administration
Jelena Mitrović1, Tanja Ilić1, Ivan Jančić2, Biljana Bufan2, Miroslav Savić3, Snežana Savić1
1 Department of Pharmaceutical Technology and Cosmetology, University of Belgrade – Faculty of Pharmacy, Vojvode Stepe 450, 11000 Belgrade, Serbia
2 Department of Microbiology and Immunology, University of Belgrade – Faculty of Pharmacy, Vojvode Stepe 450, 11000 Belgrade, Serbia
3 Department of Pharmacology, University of Belgrade – Faculty of Pharmacy, Vojvode Stepe 450, 11000 Belgrade, Serbia
Estimation of endotoxin level in parenteral formulations is a prerequisite for numerous in vitro tests in preclinical studies and for future clinical development. However, the Limulus amoebocyte lysate (LAL) test in formulations containing nanoparticles could often lead to misinterpretation of results. Therefore, we tested if endotoxins could be detected in nanocrystal dispersions by the commercial gel clot assay kit. Nanocrystals of DK-I-56-1 (7‑methoxy‑2-(4‑methoxy‑d3-phenyl)-2,5-dihydro-3H-pyrazolo[4,3-c]quinolin-3-one) were prepared by wet-ball milling, lyophilized and reconstituted with water for injection prior experiment. Different dilutions of nanocrystal dispersion in LAL reagent water were prepared as well as positive and negative control. Despite difficulties to detect gel clots, they were visible in the sample at dilutions 1:75 and below. According to the protocol, the endotoxin limit was estimated to be 25.00 EU/ml, which corresponds to <12.50 EU/mg of DK-I-56-1. This value relates to the endotoxin limit for diazepam, with the similar dosing regimen as proposed for DK-I-56-1.",
journal = "NANOGVA Symposium, October 5th - 6th, 2023, Geneva, Switzerland",
title = "Estimation of endotoxin level in nanocrystal dispersion of DK-I-56-1 intended for parenteral administration",
url = "https://hdl.handle.net/21.15107/rcub_farfar_5090"
}

Mitrović, J., Ilić, T., Jančić, I., Bufan, B., Savić, M.,& Savić, S.. (2023). Estimation of endotoxin level in nanocrystal dispersion of DK-I-56-1 intended for parenteral administration. in NANOGVA Symposium, October 5th - 6th, 2023, Geneva, Switzerland.
https://hdl.handle.net/21.15107/rcub_farfar_5090

Mitrović J, Ilić T, Jančić I, Bufan B, Savić M, Savić S. Estimation of endotoxin level in nanocrystal dispersion of DK-I-56-1 intended for parenteral administration. in NANOGVA Symposium, October 5th - 6th, 2023, Geneva, Switzerland. 2023;.
https://hdl.handle.net/21.15107/rcub_farfar_5090 .

Mitrović, Jelena, Ilić, Tanja, Jančić, Ivan, Bufan, Biljana, Savić, Miroslav, Savić, Snežana, "Estimation of endotoxin level in nanocrystal dispersion of DK-I-56-1 intended for parenteral administration" in NANOGVA Symposium, October 5th - 6th, 2023, Geneva, Switzerland (2023),
https://hdl.handle.net/21.15107/rcub_farfar_5090 .

TY  - JOUR
AU  - Mirković, Duško
AU  - Beletić, Anđelo
AU  - Savić, Miroslav
AU  - Milinković, Neda
AU  - Sarić-Matutinović, Marija
AU  - Jančić, Ivan
PY  - 2023
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/4910
AB  - Occupational and environmental toxicology specialists find catecholamine fluctuations in brain tissue relevant for research of neurotoxicity, such as that induced by manganese or zinc, pesticides, industrial solvents, plastic, air pollution, or irradiation. Considering that catecholamine tissue concentrations are generally very low, their extraction requires a reliable and optimal method that will achieve maximum recovery and minimise other interferences. This study aimed to evaluate whether the aluminium (III) oxide (Al2O3, alumina) based cartridges designed for catecholamine isolation from plasma could be used for solid-phase extraction (SPE) of catecholamine from the brain tissue. To do that, we homogenised Wistar rat brain tissue with perchloric acid and compared three extraction techniques: SPE, the routine filtration through a 0.22 µm membrane filter, and their combination. In the extracts, we compared relative chromatographic catecholamine mobility measured with high performance liquid chromatography with electrochemical detection. Chromatographic patterns for norepinephrine and epinephrine were similar regardless of the extraction technique, which indicates that the alumina cartridge is good enough to isolate them from brain tissue. However, the dopamine pattern was unsatisfactory, and further experiments are needed to identify the issue and optimise the protocol. © 2023 Duško Mirković et al., published by Sciendo.  Promjene razine katekolamina (KAT) u moždanom tkivu značajne su za brojna područja profesionalne toksikologije odnosno ekotoksikologije u kojima se istražuje neurotoksičnost izazvana različitim agensima poput mangana ili cinka, pesticida, industrijskih otapala, plastike, aerozagađenja ili zračenja. Niske koncentracije KAT-a u tkivu zahtijevaju pouzdanu i učinkovitu tehniku ekstrakcije kojom se postiže maksimalni „prinos“ katekolamina i minimalni sadržaj interferirajućih spojeva. Cilj istraživanja bio je procijeniti mogu li se kolone na bazi aluminijeva (III) oksida (Al2O3), dizajnirane za izolaciju KAT-a iz plazme, koristiti za ekstrakciju čvrstom fazom (eng. solid-phase extraction – SPE) KAT-a iz moždanoga tkiva. Nakon homogenizacije tkiva Sprague Dawley štakora upotrebom perklorne kiseline, primijenjene su tri tehnike ekstrakcije: SPE, filtracija kroz 0,22 µm membranski filtar, koji je zapravo rutinska tehnika za izolaciju KAT-a iz mozga, i kombinacija tih dviju tehnika. U ekstraktima je relativna kromatografska pokretljivost KAT-a analizirana HPLC metodom s elektrokemijskom detekcijom. Ponašanje norepinefrina i epinefrina tijekom kromatografije bilo je slično, bez obzira na tehniku ekstrakcije, što upućuje na to da aluminijev oksid ima zadovoljavajuća svojstva izolirati ta dva KAT-a iz moždanoga tkiva. Međutim, uočeni su problemi s ekstrakcijom dopamina, koji zahtijevaju dodatne eksperimente kako bi se otkrio njihov uzrok i osmislio protokol optimizacije. Author keywords aluminijev oksid; aluminium oxide; brain; catecholamines; ekstrakcija čvrste faze; katekolamini; mozak; solid phase extraction; tissue; tkivo   © This record is sourced from MEDLINE/PubMed, a database of the U.S. National Library of Medicine      1of1   Top of page Cited by 0 documents Inform me when this document is cited in Scopus: Related documents Find more related documents in Scopus based on: Authors Keywords
AB  - Promjene razine katekolamina (KAT) u moždanom tkivu značajne su za brojna područja profesionalne toksikologije odnosno ekotoksikologije u kojima se istražuje neurotoksičnost izazvana različitim agensima poput mangana ili cinka, pesticida, industrijskih otapala, plastike, aerozagađenja ili zračenja. Niske koncentracije KAT-a u tkivu zahtijevaju pouzdanu i učinkovitu tehniku ekstrakcije kojom se postiže maksimalni „prinos“ katekolamina i minimalni sadržaj interferirajućih spojeva. Cilj istraživanja bio je procijeniti mogu li se kolone na bazi aluminijeva (III) oksida (Al2 O 3), dizajnirane za izolaciju KAT-a iz plazme, koristiti za ekstrakciju čvrstom fazom (eng. solid-phase extraction – SPE) KAT-a iz moždanoga tkiva. Nakon homogenizacije tkiva Sprague Dawley štakora upotrebom perklorne kiseline, primijenjene su tri tehnike ekstrakcije: SPE, filtracija kroz 0,22 μm membranski filtar, koji je zapravo rutinska tehnika za izolaciju KAT-a iz mozga, i kombinacija tih dviju tehnika. U ekstraktima je relativna kromatografska pokretljivost KAT-a analizirana HPLC metodom s elektrokemijskom detekcijom. Ponašanje norepinefrina i epinefrina tijekom kromatografije bilo je slično, bez obzira na tehniku ekstrakcije, što upućuje na to da aluminijev oksid ima zadovoljavajuća svojstva izolirati ta dva KAT-a iz moždanoga tkiva. Međutim, uočeni su problemi s ekstrakcijom dopamina, koji zahtijevaju dodatne eksperimente kako bi se otkrio njihov uzrok i osmislio protokol optimizacije.
PB  - De Gruyter Poland
T2  - Arhiv za higijenu rada i toksikologiju
T1  - Is alumina suitable for solid phase extraction of catecholamines from brain tissue?
T1  - Je li aluminijev oksid pogodan za postupak ekstrakcije čvrste faze katekolamina iz moždanoga tkiva?
VL  - 74
IS  - 2
SP  - 120
EP  - 126
DO  - 10.2478/aiht-2023-74-3706
ER  - 

@article{
author = "Mirković, Duško and Beletić, Anđelo and Savić, Miroslav and Milinković, Neda and Sarić-Matutinović, Marija and Jančić, Ivan",
year = "2023",
abstract = "Occupational and environmental toxicology specialists find catecholamine fluctuations in brain tissue relevant for research of neurotoxicity, such as that induced by manganese or zinc, pesticides, industrial solvents, plastic, air pollution, or irradiation. Considering that catecholamine tissue concentrations are generally very low, their extraction requires a reliable and optimal method that will achieve maximum recovery and minimise other interferences. This study aimed to evaluate whether the aluminium (III) oxide (Al2O3, alumina) based cartridges designed for catecholamine isolation from plasma could be used for solid-phase extraction (SPE) of catecholamine from the brain tissue. To do that, we homogenised Wistar rat brain tissue with perchloric acid and compared three extraction techniques: SPE, the routine filtration through a 0.22 µm membrane filter, and their combination. In the extracts, we compared relative chromatographic catecholamine mobility measured with high performance liquid chromatography with electrochemical detection. Chromatographic patterns for norepinephrine and epinephrine were similar regardless of the extraction technique, which indicates that the alumina cartridge is good enough to isolate them from brain tissue. However, the dopamine pattern was unsatisfactory, and further experiments are needed to identify the issue and optimise the protocol. © 2023 Duško Mirković et al., published by Sciendo.  Promjene razine katekolamina (KAT) u moždanom tkivu značajne su za brojna područja profesionalne toksikologije odnosno ekotoksikologije u kojima se istražuje neurotoksičnost izazvana različitim agensima poput mangana ili cinka, pesticida, industrijskih otapala, plastike, aerozagađenja ili zračenja. Niske koncentracije KAT-a u tkivu zahtijevaju pouzdanu i učinkovitu tehniku ekstrakcije kojom se postiže maksimalni „prinos“ katekolamina i minimalni sadržaj interferirajućih spojeva. Cilj istraživanja bio je procijeniti mogu li se kolone na bazi aluminijeva (III) oksida (Al2O3), dizajnirane za izolaciju KAT-a iz plazme, koristiti za ekstrakciju čvrstom fazom (eng. solid-phase extraction – SPE) KAT-a iz moždanoga tkiva. Nakon homogenizacije tkiva Sprague Dawley štakora upotrebom perklorne kiseline, primijenjene su tri tehnike ekstrakcije: SPE, filtracija kroz 0,22 µm membranski filtar, koji je zapravo rutinska tehnika za izolaciju KAT-a iz mozga, i kombinacija tih dviju tehnika. U ekstraktima je relativna kromatografska pokretljivost KAT-a analizirana HPLC metodom s elektrokemijskom detekcijom. Ponašanje norepinefrina i epinefrina tijekom kromatografije bilo je slično, bez obzira na tehniku ekstrakcije, što upućuje na to da aluminijev oksid ima zadovoljavajuća svojstva izolirati ta dva KAT-a iz moždanoga tkiva. Međutim, uočeni su problemi s ekstrakcijom dopamina, koji zahtijevaju dodatne eksperimente kako bi se otkrio njihov uzrok i osmislio protokol optimizacije. Author keywords aluminijev oksid; aluminium oxide; brain; catecholamines; ekstrakcija čvrste faze; katekolamini; mozak; solid phase extraction; tissue; tkivo   © This record is sourced from MEDLINE/PubMed, a database of the U.S. National Library of Medicine      1of1   Top of page Cited by 0 documents Inform me when this document is cited in Scopus: Related documents Find more related documents in Scopus based on: Authors Keywords, Promjene razine katekolamina (KAT) u moždanom tkivu značajne su za brojna područja profesionalne toksikologije odnosno ekotoksikologije u kojima se istražuje neurotoksičnost izazvana različitim agensima poput mangana ili cinka, pesticida, industrijskih otapala, plastike, aerozagađenja ili zračenja. Niske koncentracije KAT-a u tkivu zahtijevaju pouzdanu i učinkovitu tehniku ekstrakcije kojom se postiže maksimalni „prinos“ katekolamina i minimalni sadržaj interferirajućih spojeva. Cilj istraživanja bio je procijeniti mogu li se kolone na bazi aluminijeva (III) oksida (Al2 O 3), dizajnirane za izolaciju KAT-a iz plazme, koristiti za ekstrakciju čvrstom fazom (eng. solid-phase extraction – SPE) KAT-a iz moždanoga tkiva. Nakon homogenizacije tkiva Sprague Dawley štakora upotrebom perklorne kiseline, primijenjene su tri tehnike ekstrakcije: SPE, filtracija kroz 0,22 μm membranski filtar, koji je zapravo rutinska tehnika za izolaciju KAT-a iz mozga, i kombinacija tih dviju tehnika. U ekstraktima je relativna kromatografska pokretljivost KAT-a analizirana HPLC metodom s elektrokemijskom detekcijom. Ponašanje norepinefrina i epinefrina tijekom kromatografije bilo je slično, bez obzira na tehniku ekstrakcije, što upućuje na to da aluminijev oksid ima zadovoljavajuća svojstva izolirati ta dva KAT-a iz moždanoga tkiva. Međutim, uočeni su problemi s ekstrakcijom dopamina, koji zahtijevaju dodatne eksperimente kako bi se otkrio njihov uzrok i osmislio protokol optimizacije.",
publisher = "De Gruyter Poland",
journal = "Arhiv za higijenu rada i toksikologiju",
title = "Is alumina suitable for solid phase extraction of catecholamines from brain tissue?, Je li aluminijev oksid pogodan za postupak ekstrakcije čvrste faze katekolamina iz moždanoga tkiva?",
volume = "74",
number = "2",
pages = "120-126",
doi = "10.2478/aiht-2023-74-3706"
}

Mirković, D., Beletić, A., Savić, M., Milinković, N., Sarić-Matutinović, M.,& Jančić, I.. (2023). Is alumina suitable for solid phase extraction of catecholamines from brain tissue?. in Arhiv za higijenu rada i toksikologiju
De Gruyter Poland., 74(2), 120-126.
https://doi.org/10.2478/aiht-2023-74-3706

Mirković D, Beletić A, Savić M, Milinković N, Sarić-Matutinović M, Jančić I. Is alumina suitable for solid phase extraction of catecholamines from brain tissue?. in Arhiv za higijenu rada i toksikologiju. 2023;74(2):120-126.
doi:10.2478/aiht-2023-74-3706 .

Mirković, Duško, Beletić, Anđelo, Savić, Miroslav, Milinković, Neda, Sarić-Matutinović, Marija, Jančić, Ivan, "Is alumina suitable for solid phase extraction of catecholamines from brain tissue?" in Arhiv za higijenu rada i toksikologiju, 74, no. 2 (2023):120-126,
https://doi.org/10.2478/aiht-2023-74-3706 . .

TY  - GEN
AU  - Savić, Snežana
AU  - Pantelić, Ivana
AU  - Jančić, Ivan
AU  - Savić, Miroslav
PY  - 2022
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/4298
AB  - Mood, anxiety and cognitive symptoms in psychiatry and neurology represent a significant worldwide burden. Due to difficulties in disease modeling and drug delivering to the site of action, as well as gaps in in vitro/in vivo extrapolation, the efforts to elucidate the roles of stress and neuroimmune pathways in both, etiology and therapy of these symptoms are challenging, but may nevertheless result in novel mechanisms of action. Recent preclinical studies provided novel leads/drug candidates with promising mood, anxiety and cognitive effects, the intellectual property rights of which are co-owned by the project beneficiary. We aim to: (1) incorporate the selective ligands of GABAA and/or sigma-2 receptors, with code names GL-II-73, DK-I-56, MM-I-03 and CW-02-79, together with two reference sigma-2 receptor ligands (siramesine and RHM-1), into the optimized nanoparticles and target their delivery to the human induced pluripotent stem cell (hiPSC)- based tri-culture cell neuroinflammation model, or rat brain; (2) quantify the immunological/morphological/neurochemical markers in immunologically challenged hiPSC-derived neurons, astrocytes and glia cells, and (3) assess their effects on behavior and biological markers in immunologically challenged animals of both sexes subjected to chronic mild unpredictable stress. We assume that the targeted nanodelivery of selected compounds to the brain will improve their pharmacokinetic profile, fortify their beneficial effect on mood, anxiety and cognition, and help delineate the contributing neuroimmune effects presumably arising mainly from microglia. The familiarization with neuroimmune aspects and pharmacokinetic optimization will support the preclinical progress of these compounds and might provide a rationale for designing clinical trials.
T2  - 8. Kongres farmaceuta Srbije; 12.-15. oktobar, Beograd, Srbija
T1  - Neuroimmune aspects of mood, anxiety and cognitive effects of leads/drug candidates acting at GABAA and/or sigma-2 receptors: In vitro/in vivo delineation by nano- and hiPSC-based platforms
UR  - https://hdl.handle.net/21.15107/rcub_farfar_4298
ER  - 

@misc{
author = "Savić, Snežana and Pantelić, Ivana and Jančić, Ivan and Savić, Miroslav",
year = "2022",
abstract = "Mood, anxiety and cognitive symptoms in psychiatry and neurology represent a significant worldwide burden. Due to difficulties in disease modeling and drug delivering to the site of action, as well as gaps in in vitro/in vivo extrapolation, the efforts to elucidate the roles of stress and neuroimmune pathways in both, etiology and therapy of these symptoms are challenging, but may nevertheless result in novel mechanisms of action. Recent preclinical studies provided novel leads/drug candidates with promising mood, anxiety and cognitive effects, the intellectual property rights of which are co-owned by the project beneficiary. We aim to: (1) incorporate the selective ligands of GABAA and/or sigma-2 receptors, with code names GL-II-73, DK-I-56, MM-I-03 and CW-02-79, together with two reference sigma-2 receptor ligands (siramesine and RHM-1), into the optimized nanoparticles and target their delivery to the human induced pluripotent stem cell (hiPSC)- based tri-culture cell neuroinflammation model, or rat brain; (2) quantify the immunological/morphological/neurochemical markers in immunologically challenged hiPSC-derived neurons, astrocytes and glia cells, and (3) assess their effects on behavior and biological markers in immunologically challenged animals of both sexes subjected to chronic mild unpredictable stress. We assume that the targeted nanodelivery of selected compounds to the brain will improve their pharmacokinetic profile, fortify their beneficial effect on mood, anxiety and cognition, and help delineate the contributing neuroimmune effects presumably arising mainly from microglia. The familiarization with neuroimmune aspects and pharmacokinetic optimization will support the preclinical progress of these compounds and might provide a rationale for designing clinical trials.",
journal = "8. Kongres farmaceuta Srbije; 12.-15. oktobar, Beograd, Srbija",
title = "Neuroimmune aspects of mood, anxiety and cognitive effects of leads/drug candidates acting at GABAA and/or sigma-2 receptors: In vitro/in vivo delineation by nano- and hiPSC-based platforms",
url = "https://hdl.handle.net/21.15107/rcub_farfar_4298"
}

Savić, S., Pantelić, I., Jančić, I.,& Savić, M.. (2022). Neuroimmune aspects of mood, anxiety and cognitive effects of leads/drug candidates acting at GABAA and/or sigma-2 receptors: In vitro/in vivo delineation by nano- and hiPSC-based platforms. in 8. Kongres farmaceuta Srbije; 12.-15. oktobar, Beograd, Srbija.
https://hdl.handle.net/21.15107/rcub_farfar_4298

Savić S, Pantelić I, Jančić I, Savić M. Neuroimmune aspects of mood, anxiety and cognitive effects of leads/drug candidates acting at GABAA and/or sigma-2 receptors: In vitro/in vivo delineation by nano- and hiPSC-based platforms. in 8. Kongres farmaceuta Srbije; 12.-15. oktobar, Beograd, Srbija. 2022;.
https://hdl.handle.net/21.15107/rcub_farfar_4298 .

Savić, Snežana, Pantelić, Ivana, Jančić, Ivan, Savić, Miroslav, "Neuroimmune aspects of mood, anxiety and cognitive effects of leads/drug candidates acting at GABAA and/or sigma-2 receptors: In vitro/in vivo delineation by nano- and hiPSC-based platforms" in 8. Kongres farmaceuta Srbije; 12.-15. oktobar, Beograd, Srbija (2022),
https://hdl.handle.net/21.15107/rcub_farfar_4298 .

TY  - CONF
AU  - Savić, Snežana
AU  - Pantelić, Ivana
AU  - Jančić, Ivan
AU  - Savić, Miroslav
PY  - 2022
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/4297
AB  - Mood, anxiety and cognitive symptoms in psychiatry and neurology represent a significant worldwide burden. Due to difficulties in disease modeling and drug delivering to the site of action, as well as gaps in in vitro/in vivo extrapolation, the efforts to elucidate the roles of stress and neuroimmune pathways in both, etiology and therapy of these symptoms are challenging, but may nevertheless result in novel mechanisms of action. Recent preclinical studies provided novel leads/drug candidates with promising mood, anxiety and cognitive effects, the intellectual property rights of which are co-owned by the project beneficiary. We aim to: (1) incorporate the selective ligands of GABAA and/or sigma-2 receptors, with code names GL-II-73, DK-I-56, MM-I-03 and CW-02-79, together with two reference sigma-2 receptor ligands (siramesine and RHM-1), into the optimized nanoparticles and target their delivery to the human induced pluripotent stem cell (hiPSC)- based tri-culture cell neuroinflammation model, or rat brain; (2) quantify the immunological/morphological/neurochemical markers in immunologically challenged hiPSC-derived neurons, astrocytes and glia cells, and (3) assess their effects on behavior and biological markers in immunologically challenged animals of both sexes subjected to chronic mild unpredictable stress. We assume that the targeted nanodelivery of selected compounds to the brain will improve their pharmacokinetic profile, fortify their beneficial effect on mood, anxiety and cognition, and help delineate the contributing neuroimmune effects presumably arising mainly from microglia. The familiarization with neuroimmune aspects and pharmacokinetic optimization will support the preclinical progress of these compounds and might provide a rationale for designing clinical trials.
AB  - Raspoloženje, anksioznost i kognitivni simptomi u psihijatriji i neurologiji predstavljaju
značajno opterećenje za zdravstvene sisteme na globalnom nivou. Usled poteškoća u
modelovanju bolesti i isporuci lekova na mesto delovanja, kao i jaza u in vitro/in vivo
ekstrapolaciji, potreba da se osvetle uloge stresa i neuroimunskih puteva u etiologiji i terapiji
ovih simptoma je izazov, i može rezultovati u novim mehanizmima delovanja. Nedavne
prekliničke studije obezbedile su nova vodeća jedinjenja/lekove kandidate sa obećavajućim
efektima na raspoloženje, anksioznost i kogniciju, rezultujući prihvatanjem patentnih prava
čiji je suvlasnik predlagač projekta. Cilj projekta je da: (1) inkorporiramo ligande selektivne
za GABAA i/ili sigma-2 receptore, sa kodiranim imenima GL-II-73, DK-I56, MM-I-03 i
CW-02-79, zajedno sa dva referentna liganda za sigma-2 receptore (siramesin i RHM-1), u
optimizovane nanočestice i da omogućimo njihovu ciljnu isporuku u hiPSCbazirani trićelijski
model neuroinflamacije, ili mozak pacova; (2) kvantifikujemo
imunološke/morfološke/neurohemijske markere u imunološki izazvanim hiPSC-derivisanim
neuronima, astrocitima i glija ćelijama, i (3) procenimo njihove efekte na ponašanje i
biološke markere u imunološki izazvanim životinjama oba pola podvrgnutim blagom
neočekivanom stresu. Procenjujemo da će ciljana isporuka odabranih jedinjenja pomoću
nanonosača poboljšati njihove farmakokinetičke (FK) profile, ojačati njihove korisne efekte
na raspoloženje, anksioznost i kogniciju i pomoći delineaciji doprinosa neuroimunskih
efekata, po svemu sudeći, poreklom uglavnom od mikroglija ćelija. Upoznavanje sa
neuroimunskim aspektima i FK optimizacija mogu da podrže napredak u prekliničkom
razvoju ovih jedinjenja i obezbede osnov za dizajniranje prospektivnih kliničkih studija.
C3  - 8. Kongres farmaceuta Srbije; 12.-15. oktobar, Beograd, Srbija
T1  - Neuroimmune aspects of mood, anxiety and cognitive effects of leads/drug candidates acting at gabaa and/or sigma‐2 receptors: in vitro/in vivo delineation by nano‐ and hipsc‐based platforms
T1  - Neuroimunski aspekti efekata vodećih jedinjenja/lekova kandidata koji deluju preko gabaa i/ili sigma‐2 receptora na raspoloženje, anksioznost i kogniciju: in vitro/in vivo delineacija primenom nano‐ i hipsc platformi
UR  - https://hdl.handle.net/21.15107/rcub_farfar_4297
ER  - 

@conference{
author = "Savić, Snežana and Pantelić, Ivana and Jančić, Ivan and Savić, Miroslav",
year = "2022",
abstract = "Mood, anxiety and cognitive symptoms in psychiatry and neurology represent a significant worldwide burden. Due to difficulties in disease modeling and drug delivering to the site of action, as well as gaps in in vitro/in vivo extrapolation, the efforts to elucidate the roles of stress and neuroimmune pathways in both, etiology and therapy of these symptoms are challenging, but may nevertheless result in novel mechanisms of action. Recent preclinical studies provided novel leads/drug candidates with promising mood, anxiety and cognitive effects, the intellectual property rights of which are co-owned by the project beneficiary. We aim to: (1) incorporate the selective ligands of GABAA and/or sigma-2 receptors, with code names GL-II-73, DK-I-56, MM-I-03 and CW-02-79, together with two reference sigma-2 receptor ligands (siramesine and RHM-1), into the optimized nanoparticles and target their delivery to the human induced pluripotent stem cell (hiPSC)- based tri-culture cell neuroinflammation model, or rat brain; (2) quantify the immunological/morphological/neurochemical markers in immunologically challenged hiPSC-derived neurons, astrocytes and glia cells, and (3) assess their effects on behavior and biological markers in immunologically challenged animals of both sexes subjected to chronic mild unpredictable stress. We assume that the targeted nanodelivery of selected compounds to the brain will improve their pharmacokinetic profile, fortify their beneficial effect on mood, anxiety and cognition, and help delineate the contributing neuroimmune effects presumably arising mainly from microglia. The familiarization with neuroimmune aspects and pharmacokinetic optimization will support the preclinical progress of these compounds and might provide a rationale for designing clinical trials., Raspoloženje, anksioznost i kognitivni simptomi u psihijatriji i neurologiji predstavljaju
značajno opterećenje za zdravstvene sisteme na globalnom nivou. Usled poteškoća u
modelovanju bolesti i isporuci lekova na mesto delovanja, kao i jaza u in vitro/in vivo
ekstrapolaciji, potreba da se osvetle uloge stresa i neuroimunskih puteva u etiologiji i terapiji
ovih simptoma je izazov, i može rezultovati u novim mehanizmima delovanja. Nedavne
prekliničke studije obezbedile su nova vodeća jedinjenja/lekove kandidate sa obećavajućim
efektima na raspoloženje, anksioznost i kogniciju, rezultujući prihvatanjem patentnih prava
čiji je suvlasnik predlagač projekta. Cilj projekta je da: (1) inkorporiramo ligande selektivne
za GABAA i/ili sigma-2 receptore, sa kodiranim imenima GL-II-73, DK-I56, MM-I-03 i
CW-02-79, zajedno sa dva referentna liganda za sigma-2 receptore (siramesin i RHM-1), u
optimizovane nanočestice i da omogućimo njihovu ciljnu isporuku u hiPSCbazirani trićelijski
model neuroinflamacije, ili mozak pacova; (2) kvantifikujemo
imunološke/morfološke/neurohemijske markere u imunološki izazvanim hiPSC-derivisanim
neuronima, astrocitima i glija ćelijama, i (3) procenimo njihove efekte na ponašanje i
biološke markere u imunološki izazvanim životinjama oba pola podvrgnutim blagom
neočekivanom stresu. Procenjujemo da će ciljana isporuka odabranih jedinjenja pomoću
nanonosača poboljšati njihove farmakokinetičke (FK) profile, ojačati njihove korisne efekte
na raspoloženje, anksioznost i kogniciju i pomoći delineaciji doprinosa neuroimunskih
efekata, po svemu sudeći, poreklom uglavnom od mikroglija ćelija. Upoznavanje sa
neuroimunskim aspektima i FK optimizacija mogu da podrže napredak u prekliničkom
razvoju ovih jedinjenja i obezbede osnov za dizajniranje prospektivnih kliničkih studija.",
journal = "8. Kongres farmaceuta Srbije; 12.-15. oktobar, Beograd, Srbija",
title = "Neuroimmune aspects of mood, anxiety and cognitive effects of leads/drug candidates acting at gabaa and/or sigma‐2 receptors: in vitro/in vivo delineation by nano‐ and hipsc‐based platforms, Neuroimunski aspekti efekata vodećih jedinjenja/lekova kandidata koji deluju preko gabaa i/ili sigma‐2 receptora na raspoloženje, anksioznost i kogniciju: in vitro/in vivo delineacija primenom nano‐ i hipsc platformi",
url = "https://hdl.handle.net/21.15107/rcub_farfar_4297"
}

Savić, S., Pantelić, I., Jančić, I.,& Savić, M.. (2022). Neuroimmune aspects of mood, anxiety and cognitive effects of leads/drug candidates acting at gabaa and/or sigma‐2 receptors: in vitro/in vivo delineation by nano‐ and hipsc‐based platforms. in 8. Kongres farmaceuta Srbije; 12.-15. oktobar, Beograd, Srbija.
https://hdl.handle.net/21.15107/rcub_farfar_4297

Savić S, Pantelić I, Jančić I, Savić M. Neuroimmune aspects of mood, anxiety and cognitive effects of leads/drug candidates acting at gabaa and/or sigma‐2 receptors: in vitro/in vivo delineation by nano‐ and hipsc‐based platforms. in 8. Kongres farmaceuta Srbije; 12.-15. oktobar, Beograd, Srbija. 2022;.
https://hdl.handle.net/21.15107/rcub_farfar_4297 .

Savić, Snežana, Pantelić, Ivana, Jančić, Ivan, Savić, Miroslav, "Neuroimmune aspects of mood, anxiety and cognitive effects of leads/drug candidates acting at gabaa and/or sigma‐2 receptors: in vitro/in vivo delineation by nano‐ and hipsc‐based platforms" in 8. Kongres farmaceuta Srbije; 12.-15. oktobar, Beograd, Srbija (2022),
https://hdl.handle.net/21.15107/rcub_farfar_4297 .

TY  - JOUR
AU  - Mihajlović, Marija
AU  - Ninić, Ana
AU  - Ostojić, Marija
AU  - Sopić, Miron
AU  - Stefanović, Aleksandra
AU  - Vekić, Jelena
AU  - Antonić, Tamara
AU  - Zeljković, Dejan
AU  - Trifunović, Branislav
AU  - Spasojević-Kalimanovska, Vesna
AU  - Bogavac-Stanojević, Nataša
AU  - Jančić, Ivan
AU  - Zeljković, Aleksandra
PY  - 2022
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/4327
AB  - Adiponectin (ADIPOQ) as both a regulator of metabolic homeostasis and a protein involved in immune response might be of particular interest to contemporary laboratory medicine, especially in terms of minimally invasive diagnostics. The diverse roles of ADIPOQ with regard to the immune and metabolic aspects of colorectal carcinogenesis have been proposed. However, the expression of its receptors ADIPOR1 and ADIPOR2 is scarcely explored in peripheral blood mononuclear cells (PBMCs). Moreover, ADIPORs’ relationships with the immune response mediator TNF-α have not been previously investigated in the PBMCs of CRC patients. This study used both in silico and observational case–control analyses with the aim of exploring the association of ADIPOR gene expression and ADIPOQ single nucleotide polymorphisms (SNPs) with the inflammatory marker TNF-α and lipid status parameters in patients with CRC. Publicly available transcriptomic datasets (GSE47756, GSE44076) obtained from analyses of monocytes and CRC tissue samples were employed for the in silico evaluation of ADIPORs’ specific genetic traits. GSE47756 and GSE44076 datasets were processed with GSEA software to provide a genetic fingertip of different signaling pathways associated with ADIPORs’ mRNA levels. The case–control aspect of the study included the PBMC samples of 73 patients diagnosed with CRC and 80 healthy volunteers. The PCR method was carried out for the PBMC gene expression analysis (ADIPOR1, ADIPOR2, TNF-α mRNA levels) and for the subjects’ genotyping (ADIPOQ rs266729, ADIPOR1 rs7539542). GSEA showed significant associations of ADIPOR mRNA expression with gene sets related to metabolic and immune homeostasis in both datasets. The case–control study revealed the association of ADIPOR1 rs7539542 with reduced lipid status parameters in CRC. In addition, PBMC ADIPOR1 mRNA levels decreased in CRC (p < 0.001), whereas ADIPOR2 mRNA did not differ between the groups (p = 0.442). A reduction in PBMC TNF-α mRNA levels was noted in CRC (p < 0.05). Our results indicate that ADIPOR1 and ADIPOR2 play a significant role in the alteration of both metabolic and immune homeostasis during the progression of CRC. For the first time, ADIPOR1 is shown to be a specific receptor for mediating ADIPOQ’s effects in the PBMCs of CRC patients.
PB  - MDPI
T2  - International Journal of Environmental Research and Public Health
T1  - Association of Adiponectin Receptors with Metabolic and Immune Homeostasis Parameters in Colorectal Cancer: In Silico Analysis and Observational Findings
VL  - 19
IS  - 22
DO  - 10.3390/ijerph192214995
ER  - 

@article{
author = "Mihajlović, Marija and Ninić, Ana and Ostojić, Marija and Sopić, Miron and Stefanović, Aleksandra and Vekić, Jelena and Antonić, Tamara and Zeljković, Dejan and Trifunović, Branislav and Spasojević-Kalimanovska, Vesna and Bogavac-Stanojević, Nataša and Jančić, Ivan and Zeljković, Aleksandra",
year = "2022",
abstract = "Adiponectin (ADIPOQ) as both a regulator of metabolic homeostasis and a protein involved in immune response might be of particular interest to contemporary laboratory medicine, especially in terms of minimally invasive diagnostics. The diverse roles of ADIPOQ with regard to the immune and metabolic aspects of colorectal carcinogenesis have been proposed. However, the expression of its receptors ADIPOR1 and ADIPOR2 is scarcely explored in peripheral blood mononuclear cells (PBMCs). Moreover, ADIPORs’ relationships with the immune response mediator TNF-α have not been previously investigated in the PBMCs of CRC patients. This study used both in silico and observational case–control analyses with the aim of exploring the association of ADIPOR gene expression and ADIPOQ single nucleotide polymorphisms (SNPs) with the inflammatory marker TNF-α and lipid status parameters in patients with CRC. Publicly available transcriptomic datasets (GSE47756, GSE44076) obtained from analyses of monocytes and CRC tissue samples were employed for the in silico evaluation of ADIPORs’ specific genetic traits. GSE47756 and GSE44076 datasets were processed with GSEA software to provide a genetic fingertip of different signaling pathways associated with ADIPORs’ mRNA levels. The case–control aspect of the study included the PBMC samples of 73 patients diagnosed with CRC and 80 healthy volunteers. The PCR method was carried out for the PBMC gene expression analysis (ADIPOR1, ADIPOR2, TNF-α mRNA levels) and for the subjects’ genotyping (ADIPOQ rs266729, ADIPOR1 rs7539542). GSEA showed significant associations of ADIPOR mRNA expression with gene sets related to metabolic and immune homeostasis in both datasets. The case–control study revealed the association of ADIPOR1 rs7539542 with reduced lipid status parameters in CRC. In addition, PBMC ADIPOR1 mRNA levels decreased in CRC (p < 0.001), whereas ADIPOR2 mRNA did not differ between the groups (p = 0.442). A reduction in PBMC TNF-α mRNA levels was noted in CRC (p < 0.05). Our results indicate that ADIPOR1 and ADIPOR2 play a significant role in the alteration of both metabolic and immune homeostasis during the progression of CRC. For the first time, ADIPOR1 is shown to be a specific receptor for mediating ADIPOQ’s effects in the PBMCs of CRC patients.",
publisher = "MDPI",
journal = "International Journal of Environmental Research and Public Health",
title = "Association of Adiponectin Receptors with Metabolic and Immune Homeostasis Parameters in Colorectal Cancer: In Silico Analysis and Observational Findings",
volume = "19",
number = "22",
doi = "10.3390/ijerph192214995"
}

Mihajlović, M., Ninić, A., Ostojić, M., Sopić, M., Stefanović, A., Vekić, J., Antonić, T., Zeljković, D., Trifunović, B., Spasojević-Kalimanovska, V., Bogavac-Stanojević, N., Jančić, I.,& Zeljković, A.. (2022). Association of Adiponectin Receptors with Metabolic and Immune Homeostasis Parameters in Colorectal Cancer: In Silico Analysis and Observational Findings. in International Journal of Environmental Research and Public Health
MDPI., 19(22).
https://doi.org/10.3390/ijerph192214995

Mihajlović M, Ninić A, Ostojić M, Sopić M, Stefanović A, Vekić J, Antonić T, Zeljković D, Trifunović B, Spasojević-Kalimanovska V, Bogavac-Stanojević N, Jančić I, Zeljković A. Association of Adiponectin Receptors with Metabolic and Immune Homeostasis Parameters in Colorectal Cancer: In Silico Analysis and Observational Findings. in International Journal of Environmental Research and Public Health. 2022;19(22).
doi:10.3390/ijerph192214995 .

Mihajlović, Marija, Ninić, Ana, Ostojić, Marija, Sopić, Miron, Stefanović, Aleksandra, Vekić, Jelena, Antonić, Tamara, Zeljković, Dejan, Trifunović, Branislav, Spasojević-Kalimanovska, Vesna, Bogavac-Stanojević, Nataša, Jančić, Ivan, Zeljković, Aleksandra, "Association of Adiponectin Receptors with Metabolic and Immune Homeostasis Parameters in Colorectal Cancer: In Silico Analysis and Observational Findings" in International Journal of Environmental Research and Public Health, 19, no. 22 (2022),
https://doi.org/10.3390/ijerph192214995 . .

TY  - JOUR
AU  - Radojević, Branislava
AU  - Dragašević-Mišković, Nataša
AU  - Marjanović, Ana
AU  - Branković, Marija
AU  - Milovanović, Andona
AU  - Petrović, Igor
AU  - Svetel, Marina
AU  - Jančić, Ivan
AU  - Stanisavljević, Dejana
AU  - Milićević, Ognjen
AU  - Savić, Miroslav
AU  - Kostić, Vladimir
PY  - 2022
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/4082
AB  - Background: Clinical-related risk factors to freezing of gait (FOG) in Parkinson’s disease (PD) have been iden- tified. Still, the influence of genetic variations on the FOG occurrence has been poorly studied thus far. Aim: We aimed to evaluate the association of six selected polymorphisms of DRD2, ANKK1, and COMT genes with the FOG occurrence and explore the influence of ANNK1/DRD2 haplotypes on the onset of FOG in the group of PD patients. Method: PD patients (n = 234), treated with levodopa for at least two years, were genotyped for the rs4680 in COMT, rs6277, rs1076560, and rs2283265 in DRD2, and rs1800497 and rs2734849 polymorphisms in ANKK1 genes. FOG was evaluated by posing a direct question. In addition, a comprehensive set of clinical scales was applied to all patients. Results: FOG occurred in 132 (56.4%) PD patients in our cohort. Freezers were younger at PD onset, had longer disease duration, used higher levodopa daily doses and dopaminergic agents, and had higher motor and non- motor scales scores than non-freezers. FOG was more frequent among AA rs4680 COMT carriers than AG and GG rs4680 COMT carriers. Independent predictors of FOG were: disease duration of more than ten years, levodopa daily dose higher than 500 mg/day, motor status, and COMT AA genotype. AGGAA and GGAAA haplotypes were revealed as protective and vulnerability factors for FOG occurrence. Conclusion: In addition to previously identified disease- and therapy-related risk factors, our results suggested a possible contribution of dopamine-related genes to the FOG occurrence.
PB  - Elsevier Ltd
T2  - Parkinsonism and Related Disorders
T1  - The correlation between genetic factors and freezing of gait in patients with Parkinson's disease
VL  - 98
SP  - 7
EP  - 12
DO  - 10.1016/j.parkreldis.2022.03.018
ER  - 

@article{
author = "Radojević, Branislava and Dragašević-Mišković, Nataša and Marjanović, Ana and Branković, Marija and Milovanović, Andona and Petrović, Igor and Svetel, Marina and Jančić, Ivan and Stanisavljević, Dejana and Milićević, Ognjen and Savić, Miroslav and Kostić, Vladimir",
year = "2022",
abstract = "Background: Clinical-related risk factors to freezing of gait (FOG) in Parkinson’s disease (PD) have been iden- tified. Still, the influence of genetic variations on the FOG occurrence has been poorly studied thus far. Aim: We aimed to evaluate the association of six selected polymorphisms of DRD2, ANKK1, and COMT genes with the FOG occurrence and explore the influence of ANNK1/DRD2 haplotypes on the onset of FOG in the group of PD patients. Method: PD patients (n = 234), treated with levodopa for at least two years, were genotyped for the rs4680 in COMT, rs6277, rs1076560, and rs2283265 in DRD2, and rs1800497 and rs2734849 polymorphisms in ANKK1 genes. FOG was evaluated by posing a direct question. In addition, a comprehensive set of clinical scales was applied to all patients. Results: FOG occurred in 132 (56.4%) PD patients in our cohort. Freezers were younger at PD onset, had longer disease duration, used higher levodopa daily doses and dopaminergic agents, and had higher motor and non- motor scales scores than non-freezers. FOG was more frequent among AA rs4680 COMT carriers than AG and GG rs4680 COMT carriers. Independent predictors of FOG were: disease duration of more than ten years, levodopa daily dose higher than 500 mg/day, motor status, and COMT AA genotype. AGGAA and GGAAA haplotypes were revealed as protective and vulnerability factors for FOG occurrence. Conclusion: In addition to previously identified disease- and therapy-related risk factors, our results suggested a possible contribution of dopamine-related genes to the FOG occurrence.",
publisher = "Elsevier Ltd",
journal = "Parkinsonism and Related Disorders",
title = "The correlation between genetic factors and freezing of gait in patients with Parkinson's disease",
volume = "98",
pages = "7-12",
doi = "10.1016/j.parkreldis.2022.03.018"
}

Radojević, B., Dragašević-Mišković, N., Marjanović, A., Branković, M., Milovanović, A., Petrović, I., Svetel, M., Jančić, I., Stanisavljević, D., Milićević, O., Savić, M.,& Kostić, V.. (2022). The correlation between genetic factors and freezing of gait in patients with Parkinson's disease. in Parkinsonism and Related Disorders
Elsevier Ltd., 98, 7-12.
https://doi.org/10.1016/j.parkreldis.2022.03.018

Radojević B, Dragašević-Mišković N, Marjanović A, Branković M, Milovanović A, Petrović I, Svetel M, Jančić I, Stanisavljević D, Milićević O, Savić M, Kostić V. The correlation between genetic factors and freezing of gait in patients with Parkinson's disease. in Parkinsonism and Related Disorders. 2022;98:7-12.
doi:10.1016/j.parkreldis.2022.03.018 .

Radojević, Branislava, Dragašević-Mišković, Nataša, Marjanović, Ana, Branković, Marija, Milovanović, Andona, Petrović, Igor, Svetel, Marina, Jančić, Ivan, Stanisavljević, Dejana, Milićević, Ognjen, Savić, Miroslav, Kostić, Vladimir, "The correlation between genetic factors and freezing of gait in patients with Parkinson's disease" in Parkinsonism and Related Disorders, 98 (2022):7-12,
https://doi.org/10.1016/j.parkreldis.2022.03.018 . .

TY  - CONF
AU  - Obradović, Bojana
AU  - Stojkovska, Jasmina
AU  - Osmokrović, Andrea
AU  - Mišković Stanković, Vesna
AU  - Jančić, Ivan
AU  - Milenković, Marina
PY  - 2021
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/4666
AB  - Alginate hydrogels are widely used in wound dressings due to hydrophilicity, biocompatibility,
flexibility, and high sorption capacity, providing effective moisture regulation in wounds and inducing
rapid granulation and reepithelization of the damaged tissue. However, these dressings are not
bioactive so that different methodologies have been investigated to extend functionality of alginate
hydrogels.
In the present work, we show several approaches to achieve this aim by addition of different
biologically active components. These include incorporation of silver nanoparticles as potent
antimicrobial agents (1), bioactive honey components (2), activated charcoal (AC) particles as carriers
of therapeutically active agents (3) as well as the use of Zn-alginate hydrogels that release zinc ions (4).
The obtained composites were comprehensively characterized regarding composition, cytotoxicity,
antibacterial activity, release kinetics of active agents and wound treatment in a rat model.
Ag/alginate nanocomposite hydrogels releasing silver ions and/or nanoparticles exhibited high
bactericidal activity against a broad spectrum of standard and multi-drug resistant clinical bacterial
strains (Escherichia coli, Staphylococcus aureus, methicillin-resistant Staphylococcus aureus – MRSA,
Acinetobacter baumannii and Pseudomonas aeruginosa). Especially interesting results were obtained
against 13 clinical isolates of A. baumannii, which were completely extinguished over 48 h in 6 cases
(2). However, in 3 clinical isolates, antibacterial effects were not noticed implying possibility for
development of bacterial resistance to silver. In the treatment of 2nd degree burns in rats Ag/alginate
nanocomposites exhibited the same efficiency as commercial medical products (5).
Composite alginate hydrogels with immobilized AC particles impregnated with povidone iodine
(PVP-I) as a model therapeutically active agent, were developed with the aim to provide controlled
particle release in the wound without actually releasing the adsorbed substance, thus achieving the
desired activity without adverse effects by systemic absorption. The composite Ca-alginate hydrogels
induced strong bactericidal effects against two standard bacterial strains and clinical multi-resistant
wound isolates (MRSA, E. coli, P. aeruginosa, Еnterococcus faecalis and Proteus mirabilis) without
releasing PVP-I in the environment (3). Furthermore, composite Zn-alginate hydrogels released zinc
ions in addition to AC particles with adsorbed PVP-I, which induced additional microbicidal effects on
one wild yeast strain (Candida albicans). The obtained bactericidal effects were ascribed to effective
adsorption of bacteria onto AC particles and further direct contact with the adsorbed iodine, while the
antifungal activity against C. albicans was assigned to released Zn 2+.
Overall, the developed composite alginate hydrogels have shown high potentials for utilization
in variety of multifunctional wound dressings according to the specific needs.
AB  - Alginatni hidrogelovi se široko koriste u oblogama za rane zbog svoje hidrofilnosti,
biokompatibilnosti, fleksibilnosti i velikog sorpcionog kapaciteta čime obezbeđuju efikasnu regulaciju
vlažnosti rane i podstiču brzu granulaciju i reepitelizaciju oštećenog tkiva. Međutim, ove obloge nisu
bioaktivne tako da su istraživane različite metodologije kako bi se proširila funkcionalnost alginatnih
hidrogelova.
U ovom radu je prikazano nekoliko pristupa ostvarivanju tog cilja dodatkom različitih biološki
aktivnih komponenata. Ovi pristupi uključuju inkorporaciju nanočestica srebra kao potentnog
antimikrobnog agensa (1), bioaktivnih komponenata meda (2), čestica aktivnog uglja (AU) kao nosača
terapeutski aktivnih agenasa (3), kao i primenu hidrogelova Zn-alginata koji otpuštaju jone cinka.
Dobijeni kompoziti su sveobuhvatno karakterisani u pogledu sastava, citotoksičnosti, antibakterijske
aktivnosti, kinetike otpuštanja aktivnih agenasa i tretmana rana u eksperimentalnom modelu
opekotina na pacovima.
Ag/alginatni nanokompozitni hydrogelovi su usled otpuštanja jona i/ili nanočestica srebra,
pokazali izraženu baktericidnu aktivnost prema širokom spektru standardnih i kliničkih multi-
rezistentnih bakterijskih sojeva (Escherichia coli, Staphylococcus aureus, meticilin-resistentni
Staphylococcus aureus – MRSA, Acinetobacter baumannii i Pseudomonas aeruginosa). Posebno
interesantni rezultati su dobijeni u kulturama 13 kliničkih izolata A. baumannii, gde je u 6 slučajeva
postignut potpun baktericidan efekat u toku 48 h (2). Ipak, kod 3 klinička izolata nije postignuto
antibakterijsko dejstvo što ukazuje na mogućnost razvoja bakterijske rezistencije na srebro. U
tretmanu opekotina drugog stepena na pacovima, Ag/alginatni nanokompoziti su pokazali istu
efikasnost kao komercijalni medicinski proizvodi.
Kompozitni alginatni hidrogelovi sa imobilisanim česticama AU impregniranih povidon-jodom
kao model terapeutski aktivnom komponentom, su razvijeni sa ciljem da obezbede kontrolisano
otpuštanje čestica AU u rani bez otpuštanja adsorbovane supstance kako bi se na taj način postiglo
željeno dejstvo bez neželjenih efekata sistemske apsorpcije. Kompozitni Ca-alginatni hidrogelovi su
pokazali jake baktericidne efekte na dva standardna bakterijska soja i nekoliko kliničkih multi-
rezistentnih izolata iz rana (MRSA, E. coli, P. aeruginosa, Еnterococcus faecalis i Proteus mirabilis) bez
otpuštanja povidon-joda u okolinu (3). Isto tako, kompozitni Zn-alginatni hidrogelovi su otpuštali jone
cinka uz otpuštanje AU čestica sa adsorbovanim povidon-jodom što je prouzrokovalo dodatno
mikrobicidno dejstvo na jedan divlji soj gljivice Candida albicans. Dobijeni baktericidni efekti su
pripisani efikasnoj adsorpciji bakterija na čestice AU i daljem direktnom kontaktu adsorbovanog joda
sa ćelijskom membranom bakterija, dok je antifungalna aktivnost u odnosu na C. albicans pripisana
otpuštenim Zn 2+ jonima.
Može se zaključiti da su razvijeni kompozitni alginatni hdrogelovi pokazali veliki potencijal za
primenu u raznovrsnim multifunkcionalnim oblogama za rane prilagođenim specifičnim potrebama.
PB  - Savez farmaceutskih udruženja Srbije (SFUS)
C3  - Arhiv za farmaciju
T1  - Multifunctional composites based on alginate hydrogels for potential use in wound dressings
T1  - Multifunkcionalni kompoziti na bazi alginatnih hidrogelova za potencijalnu primenu u oblogama za rane
VL  - 71
IS  - 5 suplement
SP  - S22
EP  - S23
UR  - https://hdl.handle.net/21.15107/rcub_farfar_4666
ER  - 

@conference{
author = "Obradović, Bojana and Stojkovska, Jasmina and Osmokrović, Andrea and Mišković Stanković, Vesna and Jančić, Ivan and Milenković, Marina",
year = "2021",
abstract = "Alginate hydrogels are widely used in wound dressings due to hydrophilicity, biocompatibility,
flexibility, and high sorption capacity, providing effective moisture regulation in wounds and inducing
rapid granulation and reepithelization of the damaged tissue. However, these dressings are not
bioactive so that different methodologies have been investigated to extend functionality of alginate
hydrogels.
In the present work, we show several approaches to achieve this aim by addition of different
biologically active components. These include incorporation of silver nanoparticles as potent
antimicrobial agents (1), bioactive honey components (2), activated charcoal (AC) particles as carriers
of therapeutically active agents (3) as well as the use of Zn-alginate hydrogels that release zinc ions (4).
The obtained composites were comprehensively characterized regarding composition, cytotoxicity,
antibacterial activity, release kinetics of active agents and wound treatment in a rat model.
Ag/alginate nanocomposite hydrogels releasing silver ions and/or nanoparticles exhibited high
bactericidal activity against a broad spectrum of standard and multi-drug resistant clinical bacterial
strains (Escherichia coli, Staphylococcus aureus, methicillin-resistant Staphylococcus aureus – MRSA,
Acinetobacter baumannii and Pseudomonas aeruginosa). Especially interesting results were obtained
against 13 clinical isolates of A. baumannii, which were completely extinguished over 48 h in 6 cases
(2). However, in 3 clinical isolates, antibacterial effects were not noticed implying possibility for
development of bacterial resistance to silver. In the treatment of 2nd degree burns in rats Ag/alginate
nanocomposites exhibited the same efficiency as commercial medical products (5).
Composite alginate hydrogels with immobilized AC particles impregnated with povidone iodine
(PVP-I) as a model therapeutically active agent, were developed with the aim to provide controlled
particle release in the wound without actually releasing the adsorbed substance, thus achieving the
desired activity without adverse effects by systemic absorption. The composite Ca-alginate hydrogels
induced strong bactericidal effects against two standard bacterial strains and clinical multi-resistant
wound isolates (MRSA, E. coli, P. aeruginosa, Еnterococcus faecalis and Proteus mirabilis) without
releasing PVP-I in the environment (3). Furthermore, composite Zn-alginate hydrogels released zinc
ions in addition to AC particles with adsorbed PVP-I, which induced additional microbicidal effects on
one wild yeast strain (Candida albicans). The obtained bactericidal effects were ascribed to effective
adsorption of bacteria onto AC particles and further direct contact with the adsorbed iodine, while the
antifungal activity against C. albicans was assigned to released Zn 2+.
Overall, the developed composite alginate hydrogels have shown high potentials for utilization
in variety of multifunctional wound dressings according to the specific needs., Alginatni hidrogelovi se široko koriste u oblogama za rane zbog svoje hidrofilnosti,
biokompatibilnosti, fleksibilnosti i velikog sorpcionog kapaciteta čime obezbeđuju efikasnu regulaciju
vlažnosti rane i podstiču brzu granulaciju i reepitelizaciju oštećenog tkiva. Međutim, ove obloge nisu
bioaktivne tako da su istraživane različite metodologije kako bi se proširila funkcionalnost alginatnih
hidrogelova.
U ovom radu je prikazano nekoliko pristupa ostvarivanju tog cilja dodatkom različitih biološki
aktivnih komponenata. Ovi pristupi uključuju inkorporaciju nanočestica srebra kao potentnog
antimikrobnog agensa (1), bioaktivnih komponenata meda (2), čestica aktivnog uglja (AU) kao nosača
terapeutski aktivnih agenasa (3), kao i primenu hidrogelova Zn-alginata koji otpuštaju jone cinka.
Dobijeni kompoziti su sveobuhvatno karakterisani u pogledu sastava, citotoksičnosti, antibakterijske
aktivnosti, kinetike otpuštanja aktivnih agenasa i tretmana rana u eksperimentalnom modelu
opekotina na pacovima.
Ag/alginatni nanokompozitni hydrogelovi su usled otpuštanja jona i/ili nanočestica srebra,
pokazali izraženu baktericidnu aktivnost prema širokom spektru standardnih i kliničkih multi-
rezistentnih bakterijskih sojeva (Escherichia coli, Staphylococcus aureus, meticilin-resistentni
Staphylococcus aureus – MRSA, Acinetobacter baumannii i Pseudomonas aeruginosa). Posebno
interesantni rezultati su dobijeni u kulturama 13 kliničkih izolata A. baumannii, gde je u 6 slučajeva
postignut potpun baktericidan efekat u toku 48 h (2). Ipak, kod 3 klinička izolata nije postignuto
antibakterijsko dejstvo što ukazuje na mogućnost razvoja bakterijske rezistencije na srebro. U
tretmanu opekotina drugog stepena na pacovima, Ag/alginatni nanokompoziti su pokazali istu
efikasnost kao komercijalni medicinski proizvodi.
Kompozitni alginatni hidrogelovi sa imobilisanim česticama AU impregniranih povidon-jodom
kao model terapeutski aktivnom komponentom, su razvijeni sa ciljem da obezbede kontrolisano
otpuštanje čestica AU u rani bez otpuštanja adsorbovane supstance kako bi se na taj način postiglo
željeno dejstvo bez neželjenih efekata sistemske apsorpcije. Kompozitni Ca-alginatni hidrogelovi su
pokazali jake baktericidne efekte na dva standardna bakterijska soja i nekoliko kliničkih multi-
rezistentnih izolata iz rana (MRSA, E. coli, P. aeruginosa, Еnterococcus faecalis i Proteus mirabilis) bez
otpuštanja povidon-joda u okolinu (3). Isto tako, kompozitni Zn-alginatni hidrogelovi su otpuštali jone
cinka uz otpuštanje AU čestica sa adsorbovanim povidon-jodom što je prouzrokovalo dodatno
mikrobicidno dejstvo na jedan divlji soj gljivice Candida albicans. Dobijeni baktericidni efekti su
pripisani efikasnoj adsorpciji bakterija na čestice AU i daljem direktnom kontaktu adsorbovanog joda
sa ćelijskom membranom bakterija, dok je antifungalna aktivnost u odnosu na C. albicans pripisana
otpuštenim Zn 2+ jonima.
Može se zaključiti da su razvijeni kompozitni alginatni hdrogelovi pokazali veliki potencijal za
primenu u raznovrsnim multifunkcionalnim oblogama za rane prilagođenim specifičnim potrebama.",
publisher = "Savez farmaceutskih udruženja Srbije (SFUS)",
journal = "Arhiv za farmaciju",
title = "Multifunctional composites based on alginate hydrogels for potential use in wound dressings, Multifunkcionalni kompoziti na bazi alginatnih hidrogelova za potencijalnu primenu u oblogama za rane",
volume = "71",
number = "5 suplement",
pages = "S22-S23",
url = "https://hdl.handle.net/21.15107/rcub_farfar_4666"
}

Obradović, B., Stojkovska, J., Osmokrović, A., Mišković Stanković, V., Jančić, I.,& Milenković, M.. (2021). Multifunctional composites based on alginate hydrogels for potential use in wound dressings. in Arhiv za farmaciju
Savez farmaceutskih udruženja Srbije (SFUS)., 71(5 suplement), S22-S23.
https://hdl.handle.net/21.15107/rcub_farfar_4666

Obradović B, Stojkovska J, Osmokrović A, Mišković Stanković V, Jančić I, Milenković M. Multifunctional composites based on alginate hydrogels for potential use in wound dressings. in Arhiv za farmaciju. 2021;71(5 suplement):S22-S23.
https://hdl.handle.net/21.15107/rcub_farfar_4666 .

Obradović, Bojana, Stojkovska, Jasmina, Osmokrović, Andrea, Mišković Stanković, Vesna, Jančić, Ivan, Milenković, Marina, "Multifunctional composites based on alginate hydrogels for potential use in wound dressings" in Arhiv za farmaciju, 71, no. 5 suplement (2021):S22-S23,
https://hdl.handle.net/21.15107/rcub_farfar_4666 .

TY  - JOUR
AU  - Bufan, Biljana
AU  - Jančić, Ivan
AU  - Stojić-Vukanić, Zorica
PY  - 2020
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/3642
AB  - Tumor necrosis factor (TNF)-α is a proinflammatory cytokine with a role in immunity to pathogens, as well as in the pathogenesis of several autoimmune/inflammatory diseases. Biological drugs targeting this cytokine and inhibiting its effects are designed. Until today, five TNF-α inhibitors are approved: infliximab, adalimumab, golimumab (monoclonal antibodies), certolizumab pegol (pegylated antigen-binding fragment of immunoglobulin), and etanercept [TNF receptor type 2-fragment crystallizable (Fc) of immunoglobulin fusion protein]. Their approved biosimilars are on the market, too. They are mainly used for the treatment of rheumatoid arthritis, inflammatory bowel disease, and psoriasis. Although TNF-α inhibitors are present in clinical practice for more than two decades and are established as an efficacious therapeutics, researchers are still occupied by revealing the complex mechanisms of their action. Namely, in addition to binding and neutralisation of soluble TNF-α, these drugs also bind/block transmembrane form of TNF-α (tmTNF-α), trigger diverse intracellular signals in tmTNF-α positive cells (a process named “reverse signalling”) or, if they have an Fc fragment, mediate killing of tmTNF-α-expressing cells by other immune cells or the complement system. Also, TNF-α inhibitors that contain Fc portion of the IgG antibody may affect Fc receptor-expressing cells and have an effector function quite independent of their TNF-α neutralisation capacity.
AB  - Faktor nekroze tumora (TNF)-a je citokin koji ima značajnu ulogu u patogenezi nekih autoimunskih/inflamatornih bolesti. Shodno tome, dizajnirani su biološki lekovi koji ciljano inhibiraju efekte koje on ostvaruje posredstvom svojih receptora. Do danas je odobreno pet lekova koji inhibiraju TNF-a: infliksimab, adalimumab, golimumab (monoklonska antitela), certolizumab pegol (pegilovani antigen-vezujući fragment imunoglobulina) i etanercept [TNF receptor 2-kristalizujući fragment (Fc) imunoglobulina fuzioni protein]. Takođe, brojni biosimilari ovih lekova su odobreni za primenu. Glavne indikacije za primenu anti-TNF-a lekova su: reumatoidni artritis, inflamatorne bolesti creva, psorijaza. Iako se TNF-a inhibitori više od dve decenije uspešno koriste u kliničkoj praksi, složeni mehanizmi njihovog delovanja još uvek nisu potpuno poznati. Naime, pokazano je da se ovi lekovi, osim vezivanja i neutralizacije solubilnog TNF-a, mogu vezati i za transmembransku formu ovog citokina i blokirati je i/ili pokrenuti prenos signala u ćeliju koja ispoljava ovaj molekul ("reverzni prenos signala"). Takođe, ovi lekovi, ukoliko poseduju Fc fragment, mogu posredovati i u ubijanju ćelija koje ispoljavaju membransku formu TNF-a aktivacijom drugih ćelija imunskog sistema ili sistema komplementa ili modulisati funkciju ćelija koje ispoljavaju receptore za Fc fragmanet i ostvarivati efektorske funkcije nezavisno od njihove sposobnosti da blokiraju/neutrališu TNF-a.
PB  - Beograd : Savez farmaceutskih udruženja Srbije
T2  - Arhiv za farmaciju
T1  - Inhibitors of tumor necrosis factor-α and mechanisms of their action
T1  - Inhibitori faktora nekroze tumora–α i mehanizmi njihovog dejstva
VL  - 70
IS  - 3
SP  - 109
EP  - 129
DO  - 10.5937/arhfarm2003109B
ER  - 

@article{
author = "Bufan, Biljana and Jančić, Ivan and Stojić-Vukanić, Zorica",
year = "2020",
abstract = "Tumor necrosis factor (TNF)-α is a proinflammatory cytokine with a role in immunity to pathogens, as well as in the pathogenesis of several autoimmune/inflammatory diseases. Biological drugs targeting this cytokine and inhibiting its effects are designed. Until today, five TNF-α inhibitors are approved: infliximab, adalimumab, golimumab (monoclonal antibodies), certolizumab pegol (pegylated antigen-binding fragment of immunoglobulin), and etanercept [TNF receptor type 2-fragment crystallizable (Fc) of immunoglobulin fusion protein]. Their approved biosimilars are on the market, too. They are mainly used for the treatment of rheumatoid arthritis, inflammatory bowel disease, and psoriasis. Although TNF-α inhibitors are present in clinical practice for more than two decades and are established as an efficacious therapeutics, researchers are still occupied by revealing the complex mechanisms of their action. Namely, in addition to binding and neutralisation of soluble TNF-α, these drugs also bind/block transmembrane form of TNF-α (tmTNF-α), trigger diverse intracellular signals in tmTNF-α positive cells (a process named “reverse signalling”) or, if they have an Fc fragment, mediate killing of tmTNF-α-expressing cells by other immune cells or the complement system. Also, TNF-α inhibitors that contain Fc portion of the IgG antibody may affect Fc receptor-expressing cells and have an effector function quite independent of their TNF-α neutralisation capacity., Faktor nekroze tumora (TNF)-a je citokin koji ima značajnu ulogu u patogenezi nekih autoimunskih/inflamatornih bolesti. Shodno tome, dizajnirani su biološki lekovi koji ciljano inhibiraju efekte koje on ostvaruje posredstvom svojih receptora. Do danas je odobreno pet lekova koji inhibiraju TNF-a: infliksimab, adalimumab, golimumab (monoklonska antitela), certolizumab pegol (pegilovani antigen-vezujući fragment imunoglobulina) i etanercept [TNF receptor 2-kristalizujući fragment (Fc) imunoglobulina fuzioni protein]. Takođe, brojni biosimilari ovih lekova su odobreni za primenu. Glavne indikacije za primenu anti-TNF-a lekova su: reumatoidni artritis, inflamatorne bolesti creva, psorijaza. Iako se TNF-a inhibitori više od dve decenije uspešno koriste u kliničkoj praksi, složeni mehanizmi njihovog delovanja još uvek nisu potpuno poznati. Naime, pokazano je da se ovi lekovi, osim vezivanja i neutralizacije solubilnog TNF-a, mogu vezati i za transmembransku formu ovog citokina i blokirati je i/ili pokrenuti prenos signala u ćeliju koja ispoljava ovaj molekul ("reverzni prenos signala"). Takođe, ovi lekovi, ukoliko poseduju Fc fragment, mogu posredovati i u ubijanju ćelija koje ispoljavaju membransku formu TNF-a aktivacijom drugih ćelija imunskog sistema ili sistema komplementa ili modulisati funkciju ćelija koje ispoljavaju receptore za Fc fragmanet i ostvarivati efektorske funkcije nezavisno od njihove sposobnosti da blokiraju/neutrališu TNF-a.",
publisher = "Beograd : Savez farmaceutskih udruženja Srbije",
journal = "Arhiv za farmaciju",
title = "Inhibitors of tumor necrosis factor-α and mechanisms of their action, Inhibitori faktora nekroze tumora–α i mehanizmi njihovog dejstva",
volume = "70",
number = "3",
pages = "109-129",
doi = "10.5937/arhfarm2003109B"
}

Bufan, B., Jančić, I.,& Stojić-Vukanić, Z.. (2020). Inhibitors of tumor necrosis factor-α and mechanisms of their action. in Arhiv za farmaciju
Beograd : Savez farmaceutskih udruženja Srbije., 70(3), 109-129.
https://doi.org/10.5937/arhfarm2003109B

Bufan B, Jančić I, Stojić-Vukanić Z. Inhibitors of tumor necrosis factor-α and mechanisms of their action. in Arhiv za farmaciju. 2020;70(3):109-129.
doi:10.5937/arhfarm2003109B .

Bufan, Biljana, Jančić, Ivan, Stojić-Vukanić, Zorica, "Inhibitors of tumor necrosis factor-α and mechanisms of their action" in Arhiv za farmaciju, 70, no. 3 (2020):109-129,
https://doi.org/10.5937/arhfarm2003109B . .

TY  - JOUR
AU  - Osmokrović, Andrea
AU  - Jančić, Ivan
AU  - Janković-Castvan, Ivona
AU  - Petrović, Predrag
AU  - Milenković, Marina
AU  - Obradović, Bojana
PY  - 2019
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/3308
AB  - Composites based on Zn-alginate hydrogels in the form of beads were produced by extrusion of a suspension containing 0.5 % w/w of alginate and 20 % w/w of activated charcoal (AC) with the intent to simultaneously release two active agents, Zn2+ and AC particles, in a physiological-like environment. The obtained composite beads were analyzed by FE-SEM and characterized regarding textural parameters, as well as Zn2+ and AC release kinetics in the physiological saline solution. Zn(2+)ions were quickly released reaching the equilibrium concentration within the first hour in the contrary to the release of AC particles, which was described by internal diffusion with the apparent diffusion coefficient of approximately 10(-13) m(2) s(-1). Potential functionality of the obtained beads was evaluated regarding antibacterial activity in suspensions of the standard bacterial strain Escherichia coli 25922. The observed strong bactericidal effects were related to the quick release of Zn2+ that was not affected by AC. Thus, taking into account results of this study, as well as high sorption capacity of alginate hydrogel, efficiency of AC to adsorb malodor and tissue degradation products and positive effects of Zn2+ on wound healing, the obtained composites have shown promising potentials for applications as multifunctional wound dressings.
PB  - Savez hemijskih inženjera, Beograd
T2  - Hemijska industrija
T1  - Novel composite zinc-alginate hydrogels with activated charcoal aimed for potential applications in multifunctional primary wound dressings
VL  - 73
IS  - 1
SP  - 37
EP  - 46
DO  - 10.2298/HEMIND180629003O
ER  - 

@article{
author = "Osmokrović, Andrea and Jančić, Ivan and Janković-Castvan, Ivona and Petrović, Predrag and Milenković, Marina and Obradović, Bojana",
year = "2019",
abstract = "Composites based on Zn-alginate hydrogels in the form of beads were produced by extrusion of a suspension containing 0.5 % w/w of alginate and 20 % w/w of activated charcoal (AC) with the intent to simultaneously release two active agents, Zn2+ and AC particles, in a physiological-like environment. The obtained composite beads were analyzed by FE-SEM and characterized regarding textural parameters, as well as Zn2+ and AC release kinetics in the physiological saline solution. Zn(2+)ions were quickly released reaching the equilibrium concentration within the first hour in the contrary to the release of AC particles, which was described by internal diffusion with the apparent diffusion coefficient of approximately 10(-13) m(2) s(-1). Potential functionality of the obtained beads was evaluated regarding antibacterial activity in suspensions of the standard bacterial strain Escherichia coli 25922. The observed strong bactericidal effects were related to the quick release of Zn2+ that was not affected by AC. Thus, taking into account results of this study, as well as high sorption capacity of alginate hydrogel, efficiency of AC to adsorb malodor and tissue degradation products and positive effects of Zn2+ on wound healing, the obtained composites have shown promising potentials for applications as multifunctional wound dressings.",
publisher = "Savez hemijskih inženjera, Beograd",
journal = "Hemijska industrija",
title = "Novel composite zinc-alginate hydrogels with activated charcoal aimed for potential applications in multifunctional primary wound dressings",
volume = "73",
number = "1",
pages = "37-46",
doi = "10.2298/HEMIND180629003O"
}

Osmokrović, A., Jančić, I., Janković-Castvan, I., Petrović, P., Milenković, M.,& Obradović, B.. (2019). Novel composite zinc-alginate hydrogels with activated charcoal aimed for potential applications in multifunctional primary wound dressings. in Hemijska industrija
Savez hemijskih inženjera, Beograd., 73(1), 37-46.
https://doi.org/10.2298/HEMIND180629003O

Osmokrović A, Jančić I, Janković-Castvan I, Petrović P, Milenković M, Obradović B. Novel composite zinc-alginate hydrogels with activated charcoal aimed for potential applications in multifunctional primary wound dressings. in Hemijska industrija. 2019;73(1):37-46.
doi:10.2298/HEMIND180629003O .

Osmokrović, Andrea, Jančić, Ivan, Janković-Castvan, Ivona, Petrović, Predrag, Milenković, Marina, Obradović, Bojana, "Novel composite zinc-alginate hydrogels with activated charcoal aimed for potential applications in multifunctional primary wound dressings" in Hemijska industrija, 73, no. 1 (2019):37-46,
https://doi.org/10.2298/HEMIND180629003O . .

TY  - JOUR
AU  - Osmokrović, Andrea
AU  - Jančić, Ivan
AU  - Vunduk, Jovana
AU  - Petrović, Predrag
AU  - Milenković, Marina
AU  - Obradović, Bojana
PY  - 2018
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/3240
AB  - New composites based on Ca-alginate hydrogels were produced that release activated charcoal (AC) particles with adsorbed povidone iodine (PVP-I) as a model antimicrobial substance in a physiological-like environment. Composite beads with different alginate (0.5-1.5% w/w) and AC (1-20% w/w) concentrations were analyzed by FE-SEM and characterized regarding textural parameters, swelling, and AC release kinetics. PVP-I was easily adsorbed onto AC particles within the optimized beads (0.5% w/w alginate, 20% w/w AC) as indicated by UV-vis spectroscopy, EDX and FT-IR analyses. The obtained beads have shown strong bactericidal effects against two standard bacterial strains (Staphylococcus aureus and Pseudomonas aeruginosa) and clinical multi-resistant wound isolates (MRSA, Escherichia coli, Pseudomonas aeruginosa, Enterococcus faecalis and Proteus mirabilis) and, at the same time, exhibited negligible PVP-I desorption in physiological saline solution. Thus, the obtained composites could provide utilization of potent antiseptics such as iodine, in wound dressings, without the concern of systemic absorption.
PB  - Elsevier Sci Ltd, Oxford
T2  - Carbohydrate Polymers
T1  - Achieving high antimicrobial activity: Composite alginate hydrogel beads releasing activated charcoal with an immobilized active agent
VL  - 196
SP  - 279
EP  - 288
DO  - 10.1016/j.carbpol.2018.05.045
ER  - 

@article{
author = "Osmokrović, Andrea and Jančić, Ivan and Vunduk, Jovana and Petrović, Predrag and Milenković, Marina and Obradović, Bojana",
year = "2018",
abstract = "New composites based on Ca-alginate hydrogels were produced that release activated charcoal (AC) particles with adsorbed povidone iodine (PVP-I) as a model antimicrobial substance in a physiological-like environment. Composite beads with different alginate (0.5-1.5% w/w) and AC (1-20% w/w) concentrations were analyzed by FE-SEM and characterized regarding textural parameters, swelling, and AC release kinetics. PVP-I was easily adsorbed onto AC particles within the optimized beads (0.5% w/w alginate, 20% w/w AC) as indicated by UV-vis spectroscopy, EDX and FT-IR analyses. The obtained beads have shown strong bactericidal effects against two standard bacterial strains (Staphylococcus aureus and Pseudomonas aeruginosa) and clinical multi-resistant wound isolates (MRSA, Escherichia coli, Pseudomonas aeruginosa, Enterococcus faecalis and Proteus mirabilis) and, at the same time, exhibited negligible PVP-I desorption in physiological saline solution. Thus, the obtained composites could provide utilization of potent antiseptics such as iodine, in wound dressings, without the concern of systemic absorption.",
publisher = "Elsevier Sci Ltd, Oxford",
journal = "Carbohydrate Polymers",
title = "Achieving high antimicrobial activity: Composite alginate hydrogel beads releasing activated charcoal with an immobilized active agent",
volume = "196",
pages = "279-288",
doi = "10.1016/j.carbpol.2018.05.045"
}

Osmokrović, A., Jančić, I., Vunduk, J., Petrović, P., Milenković, M.,& Obradović, B.. (2018). Achieving high antimicrobial activity: Composite alginate hydrogel beads releasing activated charcoal with an immobilized active agent. in Carbohydrate Polymers
Elsevier Sci Ltd, Oxford., 196, 279-288.
https://doi.org/10.1016/j.carbpol.2018.05.045

Osmokrović A, Jančić I, Vunduk J, Petrović P, Milenković M, Obradović B. Achieving high antimicrobial activity: Composite alginate hydrogel beads releasing activated charcoal with an immobilized active agent. in Carbohydrate Polymers. 2018;196:279-288.
doi:10.1016/j.carbpol.2018.05.045 .

Osmokrović, Andrea, Jančić, Ivan, Vunduk, Jovana, Petrović, Predrag, Milenković, Marina, Obradović, Bojana, "Achieving high antimicrobial activity: Composite alginate hydrogel beads releasing activated charcoal with an immobilized active agent" in Carbohydrate Polymers, 196 (2018):279-288,
https://doi.org/10.1016/j.carbpol.2018.05.045 . .

TY  - JOUR
AU  - Stojkovska, Jasmina
AU  - Đurđević, Željka
AU  - Jančić, Ivan
AU  - Bufan, Biljana
AU  - Milenković, Marina
AU  - Janković, Radmila
AU  - Mišković-Stanković, Vesna
AU  - Obradović, Bojana
PY  - 2018
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/3169
AB  - In the present study, possibilities for using novel nanocomposites based on alginate and silver nanoparticles for wound treatment were investigated in a second-degree thermal burn model in Wistar rats. Silver nanoparticles (AgNPs) were electrochemically synthesized in alginate solutions that were further utilized to obtain the Ag/alginate solution and microfibers for subsequent in vivo studies. Daily applications of the Ag/alginate colloid solution, containing AgNPs, alginate and ascorbic acid (G3), wet Ag/alginate microfibers containing AgNPs (G5) and dry Ag/alginate microfibers containing AgNPs (G6) were compared to treatments with a commercial cream containing silver sulfadiazine (G2) and a commercial Ca-alginate wound dressing containing silver ions (G4), as well as to the untreated controls (G1). Results of the in vivo study have shown faster healing in treated wounds, which completely healed on day 19 (G4, G5 and G6) and 21 (G2 and G3) after the thermal injury, while the period for complete reepitelization of untreated wounds (G1) was 25 days. The macroscopic analysis has shown that scabs fell off between day 10 and 12 after the thermal injury induction in treated groups, whereas between day 15 and 16 in the control group. These macroscopic findings were supported by the results of histopathological analyses, which have shown enhanced granulation and reepithelization, reduced inflammation and improved organization of the extracellular matrix in treated groups without adverse effects. Among the treated groups, dressings based on Ca-alginate (G4-G6) induced enhanced healing as compared to the other two groups (G2, G3), which could be attributed to additional stimuli of released Ca2+. The obtained results indicated potentials of novel nanocomposites based on alginate and AgNPs for therapeutic applications in wound treatments.
PB  - Sage Publications Ltd, London
T2  - Journal of Biomaterials Applications
T1  - Comparative in vivo evaluation of novel formulations based on alginate and silver nanoparticles for wound treatments
VL  - 32
IS  - 9
SP  - 1197
EP  - 1211
DO  - 10.1177/0885328218759564
ER  - 

@article{
author = "Stojkovska, Jasmina and Đurđević, Željka and Jančić, Ivan and Bufan, Biljana and Milenković, Marina and Janković, Radmila and Mišković-Stanković, Vesna and Obradović, Bojana",
year = "2018",
abstract = "In the present study, possibilities for using novel nanocomposites based on alginate and silver nanoparticles for wound treatment were investigated in a second-degree thermal burn model in Wistar rats. Silver nanoparticles (AgNPs) were electrochemically synthesized in alginate solutions that were further utilized to obtain the Ag/alginate solution and microfibers for subsequent in vivo studies. Daily applications of the Ag/alginate colloid solution, containing AgNPs, alginate and ascorbic acid (G3), wet Ag/alginate microfibers containing AgNPs (G5) and dry Ag/alginate microfibers containing AgNPs (G6) were compared to treatments with a commercial cream containing silver sulfadiazine (G2) and a commercial Ca-alginate wound dressing containing silver ions (G4), as well as to the untreated controls (G1). Results of the in vivo study have shown faster healing in treated wounds, which completely healed on day 19 (G4, G5 and G6) and 21 (G2 and G3) after the thermal injury, while the period for complete reepitelization of untreated wounds (G1) was 25 days. The macroscopic analysis has shown that scabs fell off between day 10 and 12 after the thermal injury induction in treated groups, whereas between day 15 and 16 in the control group. These macroscopic findings were supported by the results of histopathological analyses, which have shown enhanced granulation and reepithelization, reduced inflammation and improved organization of the extracellular matrix in treated groups without adverse effects. Among the treated groups, dressings based on Ca-alginate (G4-G6) induced enhanced healing as compared to the other two groups (G2, G3), which could be attributed to additional stimuli of released Ca2+. The obtained results indicated potentials of novel nanocomposites based on alginate and AgNPs for therapeutic applications in wound treatments.",
publisher = "Sage Publications Ltd, London",
journal = "Journal of Biomaterials Applications",
title = "Comparative in vivo evaluation of novel formulations based on alginate and silver nanoparticles for wound treatments",
volume = "32",
number = "9",
pages = "1197-1211",
doi = "10.1177/0885328218759564"
}

Stojkovska, J., Đurđević, Ž., Jančić, I., Bufan, B., Milenković, M., Janković, R., Mišković-Stanković, V.,& Obradović, B.. (2018). Comparative in vivo evaluation of novel formulations based on alginate and silver nanoparticles for wound treatments. in Journal of Biomaterials Applications
Sage Publications Ltd, London., 32(9), 1197-1211.
https://doi.org/10.1177/0885328218759564

Stojkovska J, Đurđević Ž, Jančić I, Bufan B, Milenković M, Janković R, Mišković-Stanković V, Obradović B. Comparative in vivo evaluation of novel formulations based on alginate and silver nanoparticles for wound treatments. in Journal of Biomaterials Applications. 2018;32(9):1197-1211.
doi:10.1177/0885328218759564 .

Stojkovska, Jasmina, Đurđević, Željka, Jančić, Ivan, Bufan, Biljana, Milenković, Marina, Janković, Radmila, Mišković-Stanković, Vesna, Obradović, Bojana, "Comparative in vivo evaluation of novel formulations based on alginate and silver nanoparticles for wound treatments" in Journal of Biomaterials Applications, 32, no. 9 (2018):1197-1211,
https://doi.org/10.1177/0885328218759564 . .

TY  - JOUR
AU  - Batinić, Bojan
AU  - Santrač, Anja
AU  - Jančić, Ivan
AU  - Li, Guanguan
AU  - Vidojević, Aleksandra
AU  - Marković, Bojan
AU  - Cook, James M.
AU  - Savić, Miroslav
PY  - 2017
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/2821
AB  - We previously demonstrated that lipopolysaccharide (LPS) administered intraperitoneally (i.p.) to pregnant Wistar rat dams, at embryonic days 15 and 16 (E15/16), induced a decrease of baseline locomotor activity and diminished reactivity to amphetamine in adult female offspring. In the present study we aimed to assess the duration of LPS-induced maternal immune activation (MIA) and investigate possible changes in levels of main neurotransmitters in fetal brain during MIA. We hypothesized that the observed behavioral changes may be linked with MIA-induced disturbance of prenatal GABAergic system development, especially with alpha 5 GABA(A) receptors (alpha 5GABA(A)Rs), expression of which takes place between E14 and E17. Thereafter, we set to investigate if later potentiation of alpha 5GABA(A)Rs in offspring's preadolescence (from postnatal day 22-28) could prevent the deficit in locomotor reactivity to amphetamine observed in adulthood, at postnatal day P60. The elevation of IL-6 in amniotic fluid 6 h after LPS treatment (100 mu g/kg, i.p.) at E15 was concurrent with a significant increase of GABA and decrease of glutamate concentration in fetal brain. Moreover, repeated administration of MP-III-022, a selective positive allosteric modulator of alpha 5GABA(A)Rs, at a dose (2 mg/kg daily, i.p.) derived from a separate pharmacokinetic study, prevented the LPS-induced decrease in locomotor reactivity to amphetamine (0.5 mg/kg, i.p.) in adult females. These results were not mirrored in the parallel set of experiments with male offspring from LPS-treated rats. The results suggest that pharmacological potentiation of alpha 5GABA(A)Rs activity in preadolescence may ameliorate at least some of adverse consequences of exposure to MIA in utero.
PB  - Pergamon-Elsevier Science Ltd, Oxford
T2  - International Journal of Developmental Neuroscience
T1  - Positive modulation of alpha 5 GABA(A) receptors in preadolescence prevents reduced locomotor response to amphetamine in adult female but not male rats prenatally exposed to lipopolysaccharide
VL  - 61
SP  - 31
EP  - 39
DO  - 10.1016/j.ijdevneu.2017.06.001
ER  - 

@article{
author = "Batinić, Bojan and Santrač, Anja and Jančić, Ivan and Li, Guanguan and Vidojević, Aleksandra and Marković, Bojan and Cook, James M. and Savić, Miroslav",
year = "2017",
abstract = "We previously demonstrated that lipopolysaccharide (LPS) administered intraperitoneally (i.p.) to pregnant Wistar rat dams, at embryonic days 15 and 16 (E15/16), induced a decrease of baseline locomotor activity and diminished reactivity to amphetamine in adult female offspring. In the present study we aimed to assess the duration of LPS-induced maternal immune activation (MIA) and investigate possible changes in levels of main neurotransmitters in fetal brain during MIA. We hypothesized that the observed behavioral changes may be linked with MIA-induced disturbance of prenatal GABAergic system development, especially with alpha 5 GABA(A) receptors (alpha 5GABA(A)Rs), expression of which takes place between E14 and E17. Thereafter, we set to investigate if later potentiation of alpha 5GABA(A)Rs in offspring's preadolescence (from postnatal day 22-28) could prevent the deficit in locomotor reactivity to amphetamine observed in adulthood, at postnatal day P60. The elevation of IL-6 in amniotic fluid 6 h after LPS treatment (100 mu g/kg, i.p.) at E15 was concurrent with a significant increase of GABA and decrease of glutamate concentration in fetal brain. Moreover, repeated administration of MP-III-022, a selective positive allosteric modulator of alpha 5GABA(A)Rs, at a dose (2 mg/kg daily, i.p.) derived from a separate pharmacokinetic study, prevented the LPS-induced decrease in locomotor reactivity to amphetamine (0.5 mg/kg, i.p.) in adult females. These results were not mirrored in the parallel set of experiments with male offspring from LPS-treated rats. The results suggest that pharmacological potentiation of alpha 5GABA(A)Rs activity in preadolescence may ameliorate at least some of adverse consequences of exposure to MIA in utero.",
publisher = "Pergamon-Elsevier Science Ltd, Oxford",
journal = "International Journal of Developmental Neuroscience",
title = "Positive modulation of alpha 5 GABA(A) receptors in preadolescence prevents reduced locomotor response to amphetamine in adult female but not male rats prenatally exposed to lipopolysaccharide",
volume = "61",
pages = "31-39",
doi = "10.1016/j.ijdevneu.2017.06.001"
}

Batinić, B., Santrač, A., Jančić, I., Li, G., Vidojević, A., Marković, B., Cook, J. M.,& Savić, M.. (2017). Positive modulation of alpha 5 GABA(A) receptors in preadolescence prevents reduced locomotor response to amphetamine in adult female but not male rats prenatally exposed to lipopolysaccharide. in International Journal of Developmental Neuroscience
Pergamon-Elsevier Science Ltd, Oxford., 61, 31-39.
https://doi.org/10.1016/j.ijdevneu.2017.06.001

Batinić B, Santrač A, Jančić I, Li G, Vidojević A, Marković B, Cook JM, Savić M. Positive modulation of alpha 5 GABA(A) receptors in preadolescence prevents reduced locomotor response to amphetamine in adult female but not male rats prenatally exposed to lipopolysaccharide. in International Journal of Developmental Neuroscience. 2017;61:31-39.
doi:10.1016/j.ijdevneu.2017.06.001 .

Batinić, Bojan, Santrač, Anja, Jančić, Ivan, Li, Guanguan, Vidojević, Aleksandra, Marković, Bojan, Cook, James M., Savić, Miroslav, "Positive modulation of alpha 5 GABA(A) receptors in preadolescence prevents reduced locomotor response to amphetamine in adult female but not male rats prenatally exposed to lipopolysaccharide" in International Journal of Developmental Neuroscience, 61 (2017):31-39,
https://doi.org/10.1016/j.ijdevneu.2017.06.001 . .

TY  - JOUR
AU  - Lukić, Jovanka
AU  - Jančić, Ivan
AU  - Mirković, Nemanja
AU  - Bufan, Biljana
AU  - Đokić, Jelena
AU  - Milenković, Marina
AU  - Begović, J.
AU  - Strahinić, Ivana
AU  - Lozo, J.
PY  - 2017
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/2871
AB  - In the light of the increasing resistance of bacterial pathogens to antibiotics, one of the main global strategies in applied science is development of alternative treatments, which would be safe both for the host and from the environmental perspective. Accordingly, the aim of this study was to test whether two lactic acid bacteria (LAB) strains, Lactococcus lactis BGBU1-4 and Lactobacillus salivarius BGHO1, could be applied as safe supplements for Listeria infection. Two major research objectives were set: to compare the effects of BGBU1-4 and BGHO1 on early immune response in gut tissue of Wistar rats co-administered with Listeria monocytogenes ATCC19111 and next, to test how this applies to their usage as therapeutics in acute ATCC19111 infection. Intestinal villi (IV), Peyer's patches (PP) and mesenteric lymph nodes (MLN) were used for the analysis. The results showed that BGHO1 increased the mRNA expression of innate immune markers CD14, interleukin (IL)-1 beta and tumour necrosis factor (TNF)-alpha in PP and IV, and, in parallel, caused a decrease of listeriolysin O (LLO) mRNA expression in same tissues. In MLN of BGHO1 treated rats, LLO expression was increased, along with an increase of the expression of OX-62 mRNA and CD69, pointing to the activation of adaptive immunity. On the other hand, in BGBU1-4 treated rats, there was no reduction of LLO mRNA expression and no induction of innate immunity markers in intestinal tissue. Additionally, CD14 and IL-1 beta, as well as LLO, but not OX-62 mRNA and CD69 expression, were elevated in MLN of BGBU1-4 treated rats. However, when applied therapeutically, both, BGBU1-4 and BGHO1, lowered Listeria count in spleens of infected rats. Our results not only reveal the potential of LAB to ameliorate Listeria infections, but suggest different immunological effects of two different LAB strains, both of which could be effective in Listeria elimination.
PB  - Wageningen Academic Publishers, Wageningen
T2  - Beneficial Microbes
T1  - Lactococcus lactis and Lactobacillus salivarius differently modulate early immunological response of Wistar rats co-administered with Listeria monocytogenes
VL  - 8
IS  - 5
SP  - 809
EP  - 822
DO  - 10.3920/BM2017.0007
ER  - 

@article{
author = "Lukić, Jovanka and Jančić, Ivan and Mirković, Nemanja and Bufan, Biljana and Đokić, Jelena and Milenković, Marina and Begović, J. and Strahinić, Ivana and Lozo, J.",
year = "2017",
abstract = "In the light of the increasing resistance of bacterial pathogens to antibiotics, one of the main global strategies in applied science is development of alternative treatments, which would be safe both for the host and from the environmental perspective. Accordingly, the aim of this study was to test whether two lactic acid bacteria (LAB) strains, Lactococcus lactis BGBU1-4 and Lactobacillus salivarius BGHO1, could be applied as safe supplements for Listeria infection. Two major research objectives were set: to compare the effects of BGBU1-4 and BGHO1 on early immune response in gut tissue of Wistar rats co-administered with Listeria monocytogenes ATCC19111 and next, to test how this applies to their usage as therapeutics in acute ATCC19111 infection. Intestinal villi (IV), Peyer's patches (PP) and mesenteric lymph nodes (MLN) were used for the analysis. The results showed that BGHO1 increased the mRNA expression of innate immune markers CD14, interleukin (IL)-1 beta and tumour necrosis factor (TNF)-alpha in PP and IV, and, in parallel, caused a decrease of listeriolysin O (LLO) mRNA expression in same tissues. In MLN of BGHO1 treated rats, LLO expression was increased, along with an increase of the expression of OX-62 mRNA and CD69, pointing to the activation of adaptive immunity. On the other hand, in BGBU1-4 treated rats, there was no reduction of LLO mRNA expression and no induction of innate immunity markers in intestinal tissue. Additionally, CD14 and IL-1 beta, as well as LLO, but not OX-62 mRNA and CD69 expression, were elevated in MLN of BGBU1-4 treated rats. However, when applied therapeutically, both, BGBU1-4 and BGHO1, lowered Listeria count in spleens of infected rats. Our results not only reveal the potential of LAB to ameliorate Listeria infections, but suggest different immunological effects of two different LAB strains, both of which could be effective in Listeria elimination.",
publisher = "Wageningen Academic Publishers, Wageningen",
journal = "Beneficial Microbes",
title = "Lactococcus lactis and Lactobacillus salivarius differently modulate early immunological response of Wistar rats co-administered with Listeria monocytogenes",
volume = "8",
number = "5",
pages = "809-822",
doi = "10.3920/BM2017.0007"
}

Lukić, J., Jančić, I., Mirković, N., Bufan, B., Đokić, J., Milenković, M., Begović, J., Strahinić, I.,& Lozo, J.. (2017). Lactococcus lactis and Lactobacillus salivarius differently modulate early immunological response of Wistar rats co-administered with Listeria monocytogenes. in Beneficial Microbes
Wageningen Academic Publishers, Wageningen., 8(5), 809-822.
https://doi.org/10.3920/BM2017.0007

Lukić J, Jančić I, Mirković N, Bufan B, Đokić J, Milenković M, Begović J, Strahinić I, Lozo J. Lactococcus lactis and Lactobacillus salivarius differently modulate early immunological response of Wistar rats co-administered with Listeria monocytogenes. in Beneficial Microbes. 2017;8(5):809-822.
doi:10.3920/BM2017.0007 .

Lukić, Jovanka, Jančić, Ivan, Mirković, Nemanja, Bufan, Biljana, Đokić, Jelena, Milenković, Marina, Begović, J., Strahinić, Ivana, Lozo, J., "Lactococcus lactis and Lactobacillus salivarius differently modulate early immunological response of Wistar rats co-administered with Listeria monocytogenes" in Beneficial Microbes, 8, no. 5 (2017):809-822,
https://doi.org/10.3920/BM2017.0007 . .

TY  - CONF
AU  - Batinić, Bojan
AU  - Santrač, Anja
AU  - Jančić, Ivan
AU  - Marković, Bojan
AU  - Milić, Marija
AU  - Savić, Miroslav
PY  - 2017
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/2872
PB  - Elsevier Science BV, Amsterdam
C3  - European Neuropsychopharmacology
T1  - GABA-A alpha 5 receptor potentiation in preadolescence prevents hyporeactivity to amphetamine induced by prenatal lipopolysaccharide treatment in rat females
VL  - 27
SP  - S610
EP  - S611
UR  - https://hdl.handle.net/21.15107/rcub_farfar_2872
ER  - 

@conference{
author = "Batinić, Bojan and Santrač, Anja and Jančić, Ivan and Marković, Bojan and Milić, Marija and Savić, Miroslav",
year = "2017",
publisher = "Elsevier Science BV, Amsterdam",
journal = "European Neuropsychopharmacology",
title = "GABA-A alpha 5 receptor potentiation in preadolescence prevents hyporeactivity to amphetamine induced by prenatal lipopolysaccharide treatment in rat females",
volume = "27",
pages = "S610-S611",
url = "https://hdl.handle.net/21.15107/rcub_farfar_2872"
}

Batinić, B., Santrač, A., Jančić, I., Marković, B., Milić, M.,& Savić, M.. (2017). GABA-A alpha 5 receptor potentiation in preadolescence prevents hyporeactivity to amphetamine induced by prenatal lipopolysaccharide treatment in rat females. in European Neuropsychopharmacology
Elsevier Science BV, Amsterdam., 27, S610-S611.
https://hdl.handle.net/21.15107/rcub_farfar_2872

Batinić B, Santrač A, Jančić I, Marković B, Milić M, Savić M. GABA-A alpha 5 receptor potentiation in preadolescence prevents hyporeactivity to amphetamine induced by prenatal lipopolysaccharide treatment in rat females. in European Neuropsychopharmacology. 2017;27:S610-S611.
https://hdl.handle.net/21.15107/rcub_farfar_2872 .

Batinić, Bojan, Santrač, Anja, Jančić, Ivan, Marković, Bojan, Milić, Marija, Savić, Miroslav, "GABA-A alpha 5 receptor potentiation in preadolescence prevents hyporeactivity to amphetamine induced by prenatal lipopolysaccharide treatment in rat females" in European Neuropsychopharmacology, 27 (2017):S610-S611,
https://hdl.handle.net/21.15107/rcub_farfar_2872 .

TY  - JOUR
AU  - Pirković, Andrea
AU  - Živković, Lada
AU  - Borozan, Sunčica
AU  - Zlatković-Svenda, Mirjana
AU  - Dekanski, Dragana
AU  - Jančić, Ivan
AU  - Radak-Perović, Marija
AU  - Bajić, Vladan
AU  - Potparević, Biljana
PY  - 2016
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/2584
AB  - The effects of co-administration of dry olive leaf extract (DOLE) with standard methotrexate (MTX) therapy on the parameters of cell damage and inflammation in patients with early and long-term rheumatoid arthritis (RA) were evaluated at baseline, 3 and 6weeks. Patients were assigned to groups: the early phase RA group on MTX monotherapy (E MTX), and the two RA groups that received co-treatment with DOLE and MTX: early (E MTX+DOLE) and long-term phase patients (L-t MTX+ DOLE). Baseline values indicated increased parameters of cell damage and disruption of redox balance in all groups. After three weeks the E MTX+DOLE group maintained high catalase activity, exhibited decrease of lipid peroxidation and protein damage indicatorsthiols and nitrites, while levels of DNA damage and pro-inflammatory interleukin-6 were significantly reduced. In E MTX group catalase activity remained unaltered while significant lipid peroxidation and DNA damage reductions were seen only after six weeks. L-t MTX+DOLE group showed only modest alterations of cell damage parameters during six weeks. Combined administration of DOLE with MTX contributes to faster reduction of cell damage, restores oxidative balance and improves interleukin-6 suppression during high disease activity in early phase RA, but not in long term patients. Copyright
PB  - Wiley-Blackwell, Hoboken
T2  - Phytotherapy Research
T1  - Dry Olive Leaf Extract in Combination with Methotrexate Reduces Cell Damage in Early Rheumatoid Arthritis PatientsA Pilot Study
VL  - 30
IS  - 10
SP  - 1615
EP  - 1623
DO  - 10.1002/ptr.5662
ER  - 

@article{
author = "Pirković, Andrea and Živković, Lada and Borozan, Sunčica and Zlatković-Svenda, Mirjana and Dekanski, Dragana and Jančić, Ivan and Radak-Perović, Marija and Bajić, Vladan and Potparević, Biljana",
year = "2016",
abstract = "The effects of co-administration of dry olive leaf extract (DOLE) with standard methotrexate (MTX) therapy on the parameters of cell damage and inflammation in patients with early and long-term rheumatoid arthritis (RA) were evaluated at baseline, 3 and 6weeks. Patients were assigned to groups: the early phase RA group on MTX monotherapy (E MTX), and the two RA groups that received co-treatment with DOLE and MTX: early (E MTX+DOLE) and long-term phase patients (L-t MTX+ DOLE). Baseline values indicated increased parameters of cell damage and disruption of redox balance in all groups. After three weeks the E MTX+DOLE group maintained high catalase activity, exhibited decrease of lipid peroxidation and protein damage indicatorsthiols and nitrites, while levels of DNA damage and pro-inflammatory interleukin-6 were significantly reduced. In E MTX group catalase activity remained unaltered while significant lipid peroxidation and DNA damage reductions were seen only after six weeks. L-t MTX+DOLE group showed only modest alterations of cell damage parameters during six weeks. Combined administration of DOLE with MTX contributes to faster reduction of cell damage, restores oxidative balance and improves interleukin-6 suppression during high disease activity in early phase RA, but not in long term patients. Copyright",
publisher = "Wiley-Blackwell, Hoboken",
journal = "Phytotherapy Research",
title = "Dry Olive Leaf Extract in Combination with Methotrexate Reduces Cell Damage in Early Rheumatoid Arthritis PatientsA Pilot Study",
volume = "30",
number = "10",
pages = "1615-1623",
doi = "10.1002/ptr.5662"
}

Pirković, A., Živković, L., Borozan, S., Zlatković-Svenda, M., Dekanski, D., Jančić, I., Radak-Perović, M., Bajić, V.,& Potparević, B.. (2016). Dry Olive Leaf Extract in Combination with Methotrexate Reduces Cell Damage in Early Rheumatoid Arthritis PatientsA Pilot Study. in Phytotherapy Research
Wiley-Blackwell, Hoboken., 30(10), 1615-1623.
https://doi.org/10.1002/ptr.5662

Pirković A, Živković L, Borozan S, Zlatković-Svenda M, Dekanski D, Jančić I, Radak-Perović M, Bajić V, Potparević B. Dry Olive Leaf Extract in Combination with Methotrexate Reduces Cell Damage in Early Rheumatoid Arthritis PatientsA Pilot Study. in Phytotherapy Research. 2016;30(10):1615-1623.
doi:10.1002/ptr.5662 .

Pirković, Andrea, Živković, Lada, Borozan, Sunčica, Zlatković-Svenda, Mirjana, Dekanski, Dragana, Jančić, Ivan, Radak-Perović, Marija, Bajić, Vladan, Potparević, Biljana, "Dry Olive Leaf Extract in Combination with Methotrexate Reduces Cell Damage in Early Rheumatoid Arthritis PatientsA Pilot Study" in Phytotherapy Research, 30, no. 10 (2016):1615-1623,
https://doi.org/10.1002/ptr.5662 . .

TY  - JOUR
AU  - Stojanović, Danilo
AU  - Aleksić, Jelena M.
AU  - Jančić, Ivan
AU  - Jančić, Radiša
PY  - 2015
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/2376
AB  - Salvia officinalis (Lamiaceae), common or Dalmatian sage, is a Mediterranean aromatic and medicinal plant used in medicine since ancient times. Knowledge on current genetic patterns and genealogical history of its natural populations is required for both breeding efforts and species conservation. We used sequences of two chloroplast intergenic spacers, 3'rps16-5'trnK and rp132-trnL, from 83 individuals from eight natural populations to distinguish between anthropogenic vs natural origin of four disjunct inland populations found outside of the main Adriatic range of the species. We found seven haplotypes, high total gene diversity (H-r = 0.695) and genetic differentiation (G(ST) = 0.682), as well as a phylogeographic structure with two lineages, a sub-structured inland-Adriatic lineage (IAL, comprising inland and Adriatic sub-lineages) and a purely Adriatic lineage (PAL). All four inland and disjunct populations, which comprised the inland sub-lineage of IAL, were almost fixed for a distinct haplotype genealogically closely related to the ancestral haplotype and displayed other features of relict populations. Along with previous biogeographic data and other lines of evidence, assumptions on their anthropogenic origin were rejected. At present, a less diverse IAL (Hd = 0.426, pi = 0.00106) and a more diverse PAL (Hd = 0.403, pi = 0.00257), whose divergence was dated to the Pliocene (3.267 Mya), do not exhibit signs of recent demographic expansions and overlap on the SE Adriatic coast, a region delineated as the main glacial refugium of S. officinalis. Conservation measures accounting for the historical distinctiveness of populations and focusing on currently the most threatened populations are recommended.
PB  - Botanischer Garten & Botanische Museum Berlin-Dahlem, Berlin
T2  - Women & Health
T1  - A Mediterranean medicinal plant in the continental Balkans: A plastid DNA-based phylogeographic survey of Salvia officinalis (Lamiaceae) and its conservation implications
VL  - 45
IS  - 1
SP  - 103
EP  - 118
DO  - 10.3372/wi.45.45112
ER  - 

@article{
author = "Stojanović, Danilo and Aleksić, Jelena M. and Jančić, Ivan and Jančić, Radiša",
year = "2015",
abstract = "Salvia officinalis (Lamiaceae), common or Dalmatian sage, is a Mediterranean aromatic and medicinal plant used in medicine since ancient times. Knowledge on current genetic patterns and genealogical history of its natural populations is required for both breeding efforts and species conservation. We used sequences of two chloroplast intergenic spacers, 3'rps16-5'trnK and rp132-trnL, from 83 individuals from eight natural populations to distinguish between anthropogenic vs natural origin of four disjunct inland populations found outside of the main Adriatic range of the species. We found seven haplotypes, high total gene diversity (H-r = 0.695) and genetic differentiation (G(ST) = 0.682), as well as a phylogeographic structure with two lineages, a sub-structured inland-Adriatic lineage (IAL, comprising inland and Adriatic sub-lineages) and a purely Adriatic lineage (PAL). All four inland and disjunct populations, which comprised the inland sub-lineage of IAL, were almost fixed for a distinct haplotype genealogically closely related to the ancestral haplotype and displayed other features of relict populations. Along with previous biogeographic data and other lines of evidence, assumptions on their anthropogenic origin were rejected. At present, a less diverse IAL (Hd = 0.426, pi = 0.00106) and a more diverse PAL (Hd = 0.403, pi = 0.00257), whose divergence was dated to the Pliocene (3.267 Mya), do not exhibit signs of recent demographic expansions and overlap on the SE Adriatic coast, a region delineated as the main glacial refugium of S. officinalis. Conservation measures accounting for the historical distinctiveness of populations and focusing on currently the most threatened populations are recommended.",
publisher = "Botanischer Garten & Botanische Museum Berlin-Dahlem, Berlin",
journal = "Women & Health",
title = "A Mediterranean medicinal plant in the continental Balkans: A plastid DNA-based phylogeographic survey of Salvia officinalis (Lamiaceae) and its conservation implications",
volume = "45",
number = "1",
pages = "103-118",
doi = "10.3372/wi.45.45112"
}

Stojanović, D., Aleksić, J. M., Jančić, I.,& Jančić, R.. (2015). A Mediterranean medicinal plant in the continental Balkans: A plastid DNA-based phylogeographic survey of Salvia officinalis (Lamiaceae) and its conservation implications. in Women & Health
Botanischer Garten & Botanische Museum Berlin-Dahlem, Berlin., 45(1), 103-118.
https://doi.org/10.3372/wi.45.45112

Stojanović D, Aleksić JM, Jančić I, Jančić R. A Mediterranean medicinal plant in the continental Balkans: A plastid DNA-based phylogeographic survey of Salvia officinalis (Lamiaceae) and its conservation implications. in Women & Health. 2015;45(1):103-118.
doi:10.3372/wi.45.45112 .

Stojanović, Danilo, Aleksić, Jelena M., Jančić, Ivan, Jančić, Radiša, "A Mediterranean medicinal plant in the continental Balkans: A plastid DNA-based phylogeographic survey of Salvia officinalis (Lamiaceae) and its conservation implications" in Women & Health, 45, no. 1 (2015):103-118,
https://doi.org/10.3372/wi.45.45112 . .

TY  - JOUR
AU  - Jančić, Ivan
AU  - Arsenović-Ranin, Nevena
PY  - 2015
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/2486
AB  - Individual variation in response to drugs is an important clinical problem, which ranges from failure to respond to the drug, over adverse reactions to drugs, to interactions among drugs being administered concurrently. Numerous findings indicate that the differences in the patients response on the same drug are caused by genetic variations. This is the subject of pharmacogenetics. Although pharmacogenetics generally equated with the concept of pharmacogenomics, pharmacogenetics is primarily related to variations in a single gene that influence the on drug response, while pharmacogenomics is a broader term, which studies how all of the genes (the genome) can influence responses to drugs. In focus of this paper will be individual variation in response to drugs arising from single nucleotide polymorphisms in genes encoding the drug target proteins, enzymes that metabolize drugs, drug transporters, and polymorphisms of genes responsible for toxicity and hypersensitivity to drugs. Determination of pharmacogenetic profile of patients could point out patients who are at increased risk of adverse drug effects (for which drug should be applied at lower doses or other drugs can be used) and those in which are likely to achieve the desired therapeutic effect, and so to enable individualization of therapy.
AB  - Individualne varijacije u odgovoru na lekove važan su klinički problem i mogu dovesti do potpunog odsustva reakcije na lek i pojave neželjenih reakcija na lekove. Brojni nalazi ukazuju da su razlike u odgovoru bolesnika na isti lek uslovljene genetskim varijacijama, i predmet su istraživanja farmakogenetike. Iako se farmakogenetika uglavnom izjednačuje sa pojmom farmakogenomika, farmakogenetika se uglavnom odnosi na varijacije u jednom genu koje utiču na odgovor na lek, dok je farmakogenomika šira oblast, koja ispituje kako svi geni u genomu povezani sa metabolizmom određenog leka mogu uticati na odgovor na dati lek. U ovom radu prevashodno će biti opisane individualne varijacije u odgovoru na lekove koje nastaju usled jednonukletidnih polimorfizama u genima koji kodiraju ciljne proteine lekova, enzime koji metabolišu lekove, transportere lekova, kao i polimorfizmi gena koji su odgovorni za toksičnost i preosetljivost na lekove. Određivanje farmakogenetskog profila bolesnika moglo bi da ukaže na bolesnike koji su u povećanom riziku od pojave neželjenih efekata lekova (kod kojih bi trebalo da se primene niže doze ili drugi lekovi) i na one kod kojih će se najverovatnije postići željeni terapijski efekat, odnosno da omogući individualizaciju terapije.
PB  - Savez farmaceutskih udruženja Srbije, Beograd
T2  - Arhiv za farmaciju
T1  - Pharmacogenetics and pharmacogenomics: The impact of the single nucleotide polymorphisms in drug response
T1  - Farmakogenetika i farmakogenomika - uticaj jednonukleotidnih polimorfizama na odgovor na lekove
VL  - 65
IS  - 6
SP  - 367
EP  - 377
DO  - 10.5937/arhfarm1506367J
ER  - 

@article{
author = "Jančić, Ivan and Arsenović-Ranin, Nevena",
year = "2015",
abstract = "Individual variation in response to drugs is an important clinical problem, which ranges from failure to respond to the drug, over adverse reactions to drugs, to interactions among drugs being administered concurrently. Numerous findings indicate that the differences in the patients response on the same drug are caused by genetic variations. This is the subject of pharmacogenetics. Although pharmacogenetics generally equated with the concept of pharmacogenomics, pharmacogenetics is primarily related to variations in a single gene that influence the on drug response, while pharmacogenomics is a broader term, which studies how all of the genes (the genome) can influence responses to drugs. In focus of this paper will be individual variation in response to drugs arising from single nucleotide polymorphisms in genes encoding the drug target proteins, enzymes that metabolize drugs, drug transporters, and polymorphisms of genes responsible for toxicity and hypersensitivity to drugs. Determination of pharmacogenetic profile of patients could point out patients who are at increased risk of adverse drug effects (for which drug should be applied at lower doses or other drugs can be used) and those in which are likely to achieve the desired therapeutic effect, and so to enable individualization of therapy., Individualne varijacije u odgovoru na lekove važan su klinički problem i mogu dovesti do potpunog odsustva reakcije na lek i pojave neželjenih reakcija na lekove. Brojni nalazi ukazuju da su razlike u odgovoru bolesnika na isti lek uslovljene genetskim varijacijama, i predmet su istraživanja farmakogenetike. Iako se farmakogenetika uglavnom izjednačuje sa pojmom farmakogenomika, farmakogenetika se uglavnom odnosi na varijacije u jednom genu koje utiču na odgovor na lek, dok je farmakogenomika šira oblast, koja ispituje kako svi geni u genomu povezani sa metabolizmom određenog leka mogu uticati na odgovor na dati lek. U ovom radu prevashodno će biti opisane individualne varijacije u odgovoru na lekove koje nastaju usled jednonukletidnih polimorfizama u genima koji kodiraju ciljne proteine lekova, enzime koji metabolišu lekove, transportere lekova, kao i polimorfizmi gena koji su odgovorni za toksičnost i preosetljivost na lekove. Određivanje farmakogenetskog profila bolesnika moglo bi da ukaže na bolesnike koji su u povećanom riziku od pojave neželjenih efekata lekova (kod kojih bi trebalo da se primene niže doze ili drugi lekovi) i na one kod kojih će se najverovatnije postići željeni terapijski efekat, odnosno da omogući individualizaciju terapije.",
publisher = "Savez farmaceutskih udruženja Srbije, Beograd",
journal = "Arhiv za farmaciju",
title = "Pharmacogenetics and pharmacogenomics: The impact of the single nucleotide polymorphisms in drug response, Farmakogenetika i farmakogenomika - uticaj jednonukleotidnih polimorfizama na odgovor na lekove",
volume = "65",
number = "6",
pages = "367-377",
doi = "10.5937/arhfarm1506367J"
}

Jančić, I.,& Arsenović-Ranin, N.. (2015). Pharmacogenetics and pharmacogenomics: The impact of the single nucleotide polymorphisms in drug response. in Arhiv za farmaciju
Savez farmaceutskih udruženja Srbije, Beograd., 65(6), 367-377.
https://doi.org/10.5937/arhfarm1506367J

Jančić I, Arsenović-Ranin N. Pharmacogenetics and pharmacogenomics: The impact of the single nucleotide polymorphisms in drug response. in Arhiv za farmaciju. 2015;65(6):367-377.
doi:10.5937/arhfarm1506367J .

Jančić, Ivan, Arsenović-Ranin, Nevena, "Pharmacogenetics and pharmacogenomics: The impact of the single nucleotide polymorphisms in drug response" in Arhiv za farmaciju, 65, no. 6 (2015):367-377,
https://doi.org/10.5937/arhfarm1506367J . .

TY  - JOUR
AU  - Jančić, Ivan
AU  - Sefik-Bukilica, Mirjana
AU  - Živojinović, Slađana
AU  - Damjanov, Nemanja
AU  - Spasovski, Vesna
AU  - Kotur, Nikola
AU  - Klaassen, Kristel
AU  - Pavlović, Sonja
AU  - Bufan, Biljana
AU  - Arsenović-Ranin, Nevena
PY  - 2015
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/2331
AB  - Background: The study was undertaken to assess the influence of functional -308G/A TNF-alpha (rs 1800629) and -174G/C IL-6 (rs1800795) promoter polymorphisms on the therapeutic response to etanercept, a TNF-alpha. blocker, in patients with rheumatoid arthritis (RA). Methods: Seventy-three patients suffering from active RA were studied, at baseline and 6 and 12 months after therapy. The therapeutic response was estimated according to the European League Against Rheumatism response criteria. Patients were genotyped for -308G/A TNF-alpha and -174G/C IL-6 polymorphisms by the PCR-RFLP method, and the influence of genotype on etanercept response was assessed. Results: No difference in the percentage of responders (patients who had DAS28 improvement > 1.2) between patients with the TNF-alpha -308GG and GA and AA genotype was detected after 6 and 12 months of treatment. After 12 months of treatment the percentage of responders was significantly increased in patients with the IL-6 -174GG genotype compared with those with the GC or CC genotype (p=0.006 by Chi-square test). Evaluation of the patients according to their combined IL-6/INF-alpha genotypes showed that patients with the IL-6 -174GG / TNF-alpha -308GG genotype were more frequent among the responders compared to those with other combined genotypes (p=0.022 by Chi-square test). More precisely, all patients with the combined IL-6 -174GG / TNF-alpha -308GG genotype were responders after 12 months of etanercept treatment. Conclusions: The study suggests that patients who are genetically low TNF-alpha and IL-6 producers are the best responders to etanercept therapy.
PB  - Društvo medicinskih biohemičara Srbije, Beograd i Versita
T2  - Journal of Medical Biochemistry
T1  - Influence of Promoter Polymorphisms of the Tnf-α (-308g/A) and IL-6 (-174g/C) Genes on Therapeutic Response to Etanercept in Rheumatoid Arthritis
VL  - 34
IS  - 4
SP  - 414
EP  - 421
DO  - 10.2478/jomb-2014-0060
ER  - 

@article{
author = "Jančić, Ivan and Sefik-Bukilica, Mirjana and Živojinović, Slađana and Damjanov, Nemanja and Spasovski, Vesna and Kotur, Nikola and Klaassen, Kristel and Pavlović, Sonja and Bufan, Biljana and Arsenović-Ranin, Nevena",
year = "2015",
abstract = "Background: The study was undertaken to assess the influence of functional -308G/A TNF-alpha (rs 1800629) and -174G/C IL-6 (rs1800795) promoter polymorphisms on the therapeutic response to etanercept, a TNF-alpha. blocker, in patients with rheumatoid arthritis (RA). Methods: Seventy-three patients suffering from active RA were studied, at baseline and 6 and 12 months after therapy. The therapeutic response was estimated according to the European League Against Rheumatism response criteria. Patients were genotyped for -308G/A TNF-alpha and -174G/C IL-6 polymorphisms by the PCR-RFLP method, and the influence of genotype on etanercept response was assessed. Results: No difference in the percentage of responders (patients who had DAS28 improvement > 1.2) between patients with the TNF-alpha -308GG and GA and AA genotype was detected after 6 and 12 months of treatment. After 12 months of treatment the percentage of responders was significantly increased in patients with the IL-6 -174GG genotype compared with those with the GC or CC genotype (p=0.006 by Chi-square test). Evaluation of the patients according to their combined IL-6/INF-alpha genotypes showed that patients with the IL-6 -174GG / TNF-alpha -308GG genotype were more frequent among the responders compared to those with other combined genotypes (p=0.022 by Chi-square test). More precisely, all patients with the combined IL-6 -174GG / TNF-alpha -308GG genotype were responders after 12 months of etanercept treatment. Conclusions: The study suggests that patients who are genetically low TNF-alpha and IL-6 producers are the best responders to etanercept therapy.",
publisher = "Društvo medicinskih biohemičara Srbije, Beograd i Versita",
journal = "Journal of Medical Biochemistry",
title = "Influence of Promoter Polymorphisms of the Tnf-α (-308g/A) and IL-6 (-174g/C) Genes on Therapeutic Response to Etanercept in Rheumatoid Arthritis",
volume = "34",
number = "4",
pages = "414-421",
doi = "10.2478/jomb-2014-0060"
}

Jančić, I., Sefik-Bukilica, M., Živojinović, S., Damjanov, N., Spasovski, V., Kotur, N., Klaassen, K., Pavlović, S., Bufan, B.,& Arsenović-Ranin, N.. (2015). Influence of Promoter Polymorphisms of the Tnf-α (-308g/A) and IL-6 (-174g/C) Genes on Therapeutic Response to Etanercept in Rheumatoid Arthritis. in Journal of Medical Biochemistry
Društvo medicinskih biohemičara Srbije, Beograd i Versita., 34(4), 414-421.
https://doi.org/10.2478/jomb-2014-0060

Jančić I, Sefik-Bukilica M, Živojinović S, Damjanov N, Spasovski V, Kotur N, Klaassen K, Pavlović S, Bufan B, Arsenović-Ranin N. Influence of Promoter Polymorphisms of the Tnf-α (-308g/A) and IL-6 (-174g/C) Genes on Therapeutic Response to Etanercept in Rheumatoid Arthritis. in Journal of Medical Biochemistry. 2015;34(4):414-421.
doi:10.2478/jomb-2014-0060 .

Jančić, Ivan, Sefik-Bukilica, Mirjana, Živojinović, Slađana, Damjanov, Nemanja, Spasovski, Vesna, Kotur, Nikola, Klaassen, Kristel, Pavlović, Sonja, Bufan, Biljana, Arsenović-Ranin, Nevena, "Influence of Promoter Polymorphisms of the Tnf-α (-308g/A) and IL-6 (-174g/C) Genes on Therapeutic Response to Etanercept in Rheumatoid Arthritis" in Journal of Medical Biochemistry, 34, no. 4 (2015):414-421,
https://doi.org/10.2478/jomb-2014-0060 . .

TY  - CONF
AU  - Zvicer, Jovana S
AU  - Girandon, L.
AU  - Potocar, U.
AU  - Froehlich, M.
AU  - Jančić, Ivan
AU  - Bufan, Biljana
AU  - Milenković, Marina
AU  - Stojkovska, J.
AU  - Mišković-Stanković, Vesna
AU  - Obradović, Bojana
PY  - 2014
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/2220
PB  - Wiley-Blackwell, Hoboken
C3  - Journal of Tissue Engineering and Regenerative Medicine
T1  - Cytotoxicity studies of novel Ag/alginate nanocomposites aimed for wound treatment
VL  - 8
IS  - Supplement 1
SP  - 345
EP  - 345
DO  - 10.1002/term.1932
ER  - 

@conference{
author = "Zvicer, Jovana S and Girandon, L. and Potocar, U. and Froehlich, M. and Jančić, Ivan and Bufan, Biljana and Milenković, Marina and Stojkovska, J. and Mišković-Stanković, Vesna and Obradović, Bojana",
year = "2014",
publisher = "Wiley-Blackwell, Hoboken",
journal = "Journal of Tissue Engineering and Regenerative Medicine",
title = "Cytotoxicity studies of novel Ag/alginate nanocomposites aimed for wound treatment",
volume = "8",
number = "Supplement 1",
pages = "345-345",
doi = "10.1002/term.1932"
}

Zvicer, J. S., Girandon, L., Potocar, U., Froehlich, M., Jančić, I., Bufan, B., Milenković, M., Stojkovska, J., Mišković-Stanković, V.,& Obradović, B.. (2014). Cytotoxicity studies of novel Ag/alginate nanocomposites aimed for wound treatment. in Journal of Tissue Engineering and Regenerative Medicine
Wiley-Blackwell, Hoboken., 8(Supplement 1), 345-345.
https://doi.org/10.1002/term.1932

Zvicer JS, Girandon L, Potocar U, Froehlich M, Jančić I, Bufan B, Milenković M, Stojkovska J, Mišković-Stanković V, Obradović B. Cytotoxicity studies of novel Ag/alginate nanocomposites aimed for wound treatment. in Journal of Tissue Engineering and Regenerative Medicine. 2014;8(Supplement 1):345-345.
doi:10.1002/term.1932 .

Zvicer, Jovana S, Girandon, L., Potocar, U., Froehlich, M., Jančić, Ivan, Bufan, Biljana, Milenković, Marina, Stojkovska, J., Mišković-Stanković, Vesna, Obradović, Bojana, "Cytotoxicity studies of novel Ag/alginate nanocomposites aimed for wound treatment" in Journal of Tissue Engineering and Regenerative Medicine, 8, no. Supplement 1 (2014):345-345,
https://doi.org/10.1002/term.1932 . .

TY  - JOUR
AU  - Jančić, Ivan
AU  - Arsenović-Ranin, Nevena
AU  - Sefik-Bukilica, Mirjana
AU  - Živojinović, Slađana
AU  - Damjanov, Nemanja
AU  - Spasovski, Vesna
AU  - Srzentić, Sanja
AU  - Stanković, Biljana
AU  - Pavlović, Sonja
PY  - 2013
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/1998
AB  - To examine whether -174G/C interleukin-6 (IL-6) gene polymorphism, previously reported to correlate with IL-6 level, influences response to etanercept therapy in patients with rheumatoid arthritis. Seventy-seven patients with active RA were studied, at baseline and 6- and 12-month follow-up after etanercept therapy. Treatment response was estimated according to the European League Against Rheumatism response criteria. RA patients were genotyped for -174G/C IL-6 gene polymorphism by the PCR-RFLP method, and influence of genotype at this polymorphism to clinical response to etanercept was assessed. After 12 months of treatment, the percentage of responders (patients who had DAS28 improvement > 1.2) was significantly increased in patients carrying the IL-6 -174G/G genotype (95.7 %) compared with those with the G/C (75.6 %) or CC (44.4 %) genotype (p = 0.006 by Chi-square test). No significant difference in the mean values of DAS28 improvement was observed between groups with different genotype. RA patients with an IL-6 -174GG genotype respond to etanercept better than patients with GC or CC genotype. This finding, if confirmed in future studies, suggests that the -174G/C IL-6 polymorphism may be a genetic marker of responsiveness to tumor necrosis factor-alpha (TNF-alpha) blockers in RA.
PB  - Springer Heidelberg, Heidelberg
T2  - Rheumatology International
T1  - -174G/C interleukin-6 gene promoter polymorphism predicts therapeutic response to etanercept in rheumatoid arthritis
VL  - 33
IS  - 6
SP  - 1481
EP  - 1486
DO  - 10.1007/s00296-012-2586-y
ER  - 

@article{
author = "Jančić, Ivan and Arsenović-Ranin, Nevena and Sefik-Bukilica, Mirjana and Živojinović, Slađana and Damjanov, Nemanja and Spasovski, Vesna and Srzentić, Sanja and Stanković, Biljana and Pavlović, Sonja",
year = "2013",
abstract = "To examine whether -174G/C interleukin-6 (IL-6) gene polymorphism, previously reported to correlate with IL-6 level, influences response to etanercept therapy in patients with rheumatoid arthritis. Seventy-seven patients with active RA were studied, at baseline and 6- and 12-month follow-up after etanercept therapy. Treatment response was estimated according to the European League Against Rheumatism response criteria. RA patients were genotyped for -174G/C IL-6 gene polymorphism by the PCR-RFLP method, and influence of genotype at this polymorphism to clinical response to etanercept was assessed. After 12 months of treatment, the percentage of responders (patients who had DAS28 improvement > 1.2) was significantly increased in patients carrying the IL-6 -174G/G genotype (95.7 %) compared with those with the G/C (75.6 %) or CC (44.4 %) genotype (p = 0.006 by Chi-square test). No significant difference in the mean values of DAS28 improvement was observed between groups with different genotype. RA patients with an IL-6 -174GG genotype respond to etanercept better than patients with GC or CC genotype. This finding, if confirmed in future studies, suggests that the -174G/C IL-6 polymorphism may be a genetic marker of responsiveness to tumor necrosis factor-alpha (TNF-alpha) blockers in RA.",
publisher = "Springer Heidelberg, Heidelberg",
journal = "Rheumatology International",
title = "-174G/C interleukin-6 gene promoter polymorphism predicts therapeutic response to etanercept in rheumatoid arthritis",
volume = "33",
number = "6",
pages = "1481-1486",
doi = "10.1007/s00296-012-2586-y"
}

Jančić, I., Arsenović-Ranin, N., Sefik-Bukilica, M., Živojinović, S., Damjanov, N., Spasovski, V., Srzentić, S., Stanković, B.,& Pavlović, S.. (2013). -174G/C interleukin-6 gene promoter polymorphism predicts therapeutic response to etanercept in rheumatoid arthritis. in Rheumatology International
Springer Heidelberg, Heidelberg., 33(6), 1481-1486.
https://doi.org/10.1007/s00296-012-2586-y

Jančić I, Arsenović-Ranin N, Sefik-Bukilica M, Živojinović S, Damjanov N, Spasovski V, Srzentić S, Stanković B, Pavlović S. -174G/C interleukin-6 gene promoter polymorphism predicts therapeutic response to etanercept in rheumatoid arthritis. in Rheumatology International. 2013;33(6):1481-1486.
doi:10.1007/s00296-012-2586-y .

Jančić, Ivan, Arsenović-Ranin, Nevena, Sefik-Bukilica, Mirjana, Živojinović, Slađana, Damjanov, Nemanja, Spasovski, Vesna, Srzentić, Sanja, Stanković, Biljana, Pavlović, Sonja, "-174G/C interleukin-6 gene promoter polymorphism predicts therapeutic response to etanercept in rheumatoid arthritis" in Rheumatology International, 33, no. 6 (2013):1481-1486,
https://doi.org/10.1007/s00296-012-2586-y . .

TY  - CONF
AU  - Arsenović-Ranin, Nevena
AU  - Jančić, Ivan
AU  - Sefik-Bukilica, Mirjana
AU  - Živojinović, S.
AU  - Damjanov, Nemanja
AU  - Spasovski, Vesna
AU  - Srzentić, Sanja
AU  - Stanković, B.
AU  - Pavlović, S.
PY  - 2012
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/1652
PB  - Wiley-Blackwell, Hoboken
C3  - Immunology
T1  - Polymorphism at position-174 of the interleukin-6 gene influences outcome of etanercept therapy in rheumatoid arthritis
VL  - 137
SP  - 24
EP  - 24
UR  - https://hdl.handle.net/21.15107/rcub_farfar_1652
ER  - 

@conference{
author = "Arsenović-Ranin, Nevena and Jančić, Ivan and Sefik-Bukilica, Mirjana and Živojinović, S. and Damjanov, Nemanja and Spasovski, Vesna and Srzentić, Sanja and Stanković, B. and Pavlović, S.",
year = "2012",
publisher = "Wiley-Blackwell, Hoboken",
journal = "Immunology",
title = "Polymorphism at position-174 of the interleukin-6 gene influences outcome of etanercept therapy in rheumatoid arthritis",
volume = "137",
pages = "24-24",
url = "https://hdl.handle.net/21.15107/rcub_farfar_1652"
}

Arsenović-Ranin, N., Jančić, I., Sefik-Bukilica, M., Živojinović, S., Damjanov, N., Spasovski, V., Srzentić, S., Stanković, B.,& Pavlović, S.. (2012). Polymorphism at position-174 of the interleukin-6 gene influences outcome of etanercept therapy in rheumatoid arthritis. in Immunology
Wiley-Blackwell, Hoboken., 137, 24-24.
https://hdl.handle.net/21.15107/rcub_farfar_1652

Arsenović-Ranin N, Jančić I, Sefik-Bukilica M, Živojinović S, Damjanov N, Spasovski V, Srzentić S, Stanković B, Pavlović S. Polymorphism at position-174 of the interleukin-6 gene influences outcome of etanercept therapy in rheumatoid arthritis. in Immunology. 2012;137:24-24.
https://hdl.handle.net/21.15107/rcub_farfar_1652 .

Arsenović-Ranin, Nevena, Jančić, Ivan, Sefik-Bukilica, Mirjana, Živojinović, S., Damjanov, Nemanja, Spasovski, Vesna, Srzentić, Sanja, Stanković, B., Pavlović, S., "Polymorphism at position-174 of the interleukin-6 gene influences outcome of etanercept therapy in rheumatoid arthritis" in Immunology, 137 (2012):24-24,
https://hdl.handle.net/21.15107/rcub_farfar_1652 .

TY  - JOUR
AU  - Milenković, Marina
AU  - Arsenović-Ranin, Nevena
AU  - Stojić-Vukanić, Zorica
AU  - Bufan, Biljana
AU  - Vučićević, Dragana
AU  - Jančić, Ivan
PY  - 2010
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/1327
AB  - Purpose. Experimental autoimmune myocarditis (EAM) in rats is an animal model of human giant cell myocarditis and post-myocarditis dilated cardiomyopathy. The pathogenesis of EAM has not been elucidated, but there is accumulating evidence that cytokines secreted from monocytes/macrophages and T cells play a crucial role in the induction and progression of disease. Flavonoids are a large group of polyphenolic compounds abundantly present in the human diet, which scavenge oxygen radicals and have anti-inflammatory activities. Having in mind in vivo beneficial effects of flavonoid quercetin in different animal models of immunoinflammatory diseases such as experimental autoimmune encephalomyelitis and adjuvant arthritis, on the one side, and its in vitro suppressive effect on production of tumor necrosis factor-alpha (TNF-alpha), on the other side, we investigated the effects of quercetin on EAM in rats. Methods. Myocarditis was induced in Dark Agouti (DA) rats by injection of porcine cardiac myosin and quercetin at doses of 10 or 20 mg/kg was orally administered from days 0 to 21 after induction of disease. The severity of myocarditis was evaluated by determination of heart weight/body weight ratio (Hw/Bw) and histopathological examination of hearts. The levels of cytokines (TNF-alpha, IL-12, IL-17 and IL-10) in serum and lymph node cells (LNC) culture supernatants were measured by ELISA. Results. The rats treated with 20 mg/kg of quercetin had significantly decreased incidence of EAM, Hw/Bw, macroscopic and microscopic scores of hearts. Further, in EAM rats treated with quercetin levels of TNF-alpha and IL-17 were significantly lower, while the level of IL-10 was significantly higher both in serum and culture supernatants of LNC stimulated with concanavalin A compared with vehicle-treated animals. Conclusions. The present study suggests that quercetin ameliorates EAM, at least in part, by interfering production of proinflammatory (TNF-alpha and IL-17) and/or anti-inflammatory (IL-10) cytokines.
PB  - Canadian Soc Pharmaceutical Sciences, Edmonton
T2  - Journal of Pharmacy and Pharmaceutical Sciences
T1  - Quercetin Ameliorates Experimental Autoimmune Myocarditis in Rats
VL  - 13
IS  - 3
SP  - 311
EP  - 319
DO  - 10.18433/J3VS3S
ER  - 

@article{
author = "Milenković, Marina and Arsenović-Ranin, Nevena and Stojić-Vukanić, Zorica and Bufan, Biljana and Vučićević, Dragana and Jančić, Ivan",
year = "2010",
abstract = "Purpose. Experimental autoimmune myocarditis (EAM) in rats is an animal model of human giant cell myocarditis and post-myocarditis dilated cardiomyopathy. The pathogenesis of EAM has not been elucidated, but there is accumulating evidence that cytokines secreted from monocytes/macrophages and T cells play a crucial role in the induction and progression of disease. Flavonoids are a large group of polyphenolic compounds abundantly present in the human diet, which scavenge oxygen radicals and have anti-inflammatory activities. Having in mind in vivo beneficial effects of flavonoid quercetin in different animal models of immunoinflammatory diseases such as experimental autoimmune encephalomyelitis and adjuvant arthritis, on the one side, and its in vitro suppressive effect on production of tumor necrosis factor-alpha (TNF-alpha), on the other side, we investigated the effects of quercetin on EAM in rats. Methods. Myocarditis was induced in Dark Agouti (DA) rats by injection of porcine cardiac myosin and quercetin at doses of 10 or 20 mg/kg was orally administered from days 0 to 21 after induction of disease. The severity of myocarditis was evaluated by determination of heart weight/body weight ratio (Hw/Bw) and histopathological examination of hearts. The levels of cytokines (TNF-alpha, IL-12, IL-17 and IL-10) in serum and lymph node cells (LNC) culture supernatants were measured by ELISA. Results. The rats treated with 20 mg/kg of quercetin had significantly decreased incidence of EAM, Hw/Bw, macroscopic and microscopic scores of hearts. Further, in EAM rats treated with quercetin levels of TNF-alpha and IL-17 were significantly lower, while the level of IL-10 was significantly higher both in serum and culture supernatants of LNC stimulated with concanavalin A compared with vehicle-treated animals. Conclusions. The present study suggests that quercetin ameliorates EAM, at least in part, by interfering production of proinflammatory (TNF-alpha and IL-17) and/or anti-inflammatory (IL-10) cytokines.",
publisher = "Canadian Soc Pharmaceutical Sciences, Edmonton",
journal = "Journal of Pharmacy and Pharmaceutical Sciences",
title = "Quercetin Ameliorates Experimental Autoimmune Myocarditis in Rats",
volume = "13",
number = "3",
pages = "311-319",
doi = "10.18433/J3VS3S"
}

Milenković, M., Arsenović-Ranin, N., Stojić-Vukanić, Z., Bufan, B., Vučićević, D.,& Jančić, I.. (2010). Quercetin Ameliorates Experimental Autoimmune Myocarditis in Rats. in Journal of Pharmacy and Pharmaceutical Sciences
Canadian Soc Pharmaceutical Sciences, Edmonton., 13(3), 311-319.
https://doi.org/10.18433/J3VS3S

Milenković M, Arsenović-Ranin N, Stojić-Vukanić Z, Bufan B, Vučićević D, Jančić I. Quercetin Ameliorates Experimental Autoimmune Myocarditis in Rats. in Journal of Pharmacy and Pharmaceutical Sciences. 2010;13(3):311-319.
doi:10.18433/J3VS3S .

Milenković, Marina, Arsenović-Ranin, Nevena, Stojić-Vukanić, Zorica, Bufan, Biljana, Vučićević, Dragana, Jančić, Ivan, "Quercetin Ameliorates Experimental Autoimmune Myocarditis in Rats" in Journal of Pharmacy and Pharmaceutical Sciences, 13, no. 3 (2010):311-319,
https://doi.org/10.18433/J3VS3S . .

TY  - JOUR
AU  - Milenković, Marina
AU  - Arsenović-Ranin, Nevena
AU  - Božić, Dragana
AU  - Bufan, Biljana
AU  - Jančić, Ivan
AU  - Stojić-Vukanić, Zorica
PY  - 2008
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/1107
AB  - Background. Fumaric acid esters (FAE) have been proven to be effective for the systemic treatment of psoriasis and multiple sclerosis, Thl cell-mediated chronic inflammatory diseases, but their effect on autoimmune rnyocarditis has not yet been addressed. We investigated the effect of dimethyl fumarate (DMF) on myosin-induced experimental autoimmune myocarditis (EAM). Methods. Dark Agouti (DA) rats immunized with porcine cardiac myosin were orally treated with 5 and 15 mg/kg body weight (bw) DMF either from days 0-10 (early treatment groups) or from days 10-21 (late treatment groups) after induction of EAM. All rats were sacrificed on day 21 after immunization and hearts were evaluated macroscopically and microscopically. Levels of TNF-alpha and IL-10 in serum and lymph node cells culture supernatants were detected by ELISA. Results. Both early and late treatment with 15 mg/kg body weight (bw) DMF markedly C, reduced the severity of myocarditis by comparing the incidence, heart weight bw ratio, macroscopic and microscopic scores, and number of OX-6+ cells in the myocardium. Further, levels of tumor necrosis factor-alpha (TNF-alpha) in serum and culture supernatants of lymph node cells stimulated with ConA or myosin were significantly lower in DNIF-treated EAM animals compared with vehicle-treated EAM rats. There was no significant difference in serum levels of interleukin-10 between DMF- and vehicle-treated EAM rats. Conclusions. These results show for the first time that DMF ameliorates experimental autoimmune rnyocarditis and may be acted, at least in part, by interfering with the production of TNF-alpha.
PB  - Elsevier Science Inc, New York
T2  - Archives of Medical Research
T1  - Beneficial effects of dimethyl fumarate on experimental autoimmune myocarditis
VL  - 39
IS  - 7
SP  - 639
EP  - 646
DO  - 10.1016/j.arcmed.2008.07.003
ER  - 

@article{
author = "Milenković, Marina and Arsenović-Ranin, Nevena and Božić, Dragana and Bufan, Biljana and Jančić, Ivan and Stojić-Vukanić, Zorica",
year = "2008",
abstract = "Background. Fumaric acid esters (FAE) have been proven to be effective for the systemic treatment of psoriasis and multiple sclerosis, Thl cell-mediated chronic inflammatory diseases, but their effect on autoimmune rnyocarditis has not yet been addressed. We investigated the effect of dimethyl fumarate (DMF) on myosin-induced experimental autoimmune myocarditis (EAM). Methods. Dark Agouti (DA) rats immunized with porcine cardiac myosin were orally treated with 5 and 15 mg/kg body weight (bw) DMF either from days 0-10 (early treatment groups) or from days 10-21 (late treatment groups) after induction of EAM. All rats were sacrificed on day 21 after immunization and hearts were evaluated macroscopically and microscopically. Levels of TNF-alpha and IL-10 in serum and lymph node cells culture supernatants were detected by ELISA. Results. Both early and late treatment with 15 mg/kg body weight (bw) DMF markedly C, reduced the severity of myocarditis by comparing the incidence, heart weight bw ratio, macroscopic and microscopic scores, and number of OX-6+ cells in the myocardium. Further, levels of tumor necrosis factor-alpha (TNF-alpha) in serum and culture supernatants of lymph node cells stimulated with ConA or myosin were significantly lower in DNIF-treated EAM animals compared with vehicle-treated EAM rats. There was no significant difference in serum levels of interleukin-10 between DMF- and vehicle-treated EAM rats. Conclusions. These results show for the first time that DMF ameliorates experimental autoimmune rnyocarditis and may be acted, at least in part, by interfering with the production of TNF-alpha.",
publisher = "Elsevier Science Inc, New York",
journal = "Archives of Medical Research",
title = "Beneficial effects of dimethyl fumarate on experimental autoimmune myocarditis",
volume = "39",
number = "7",
pages = "639-646",
doi = "10.1016/j.arcmed.2008.07.003"
}

Milenković, M., Arsenović-Ranin, N., Božić, D., Bufan, B., Jančić, I.,& Stojić-Vukanić, Z.. (2008). Beneficial effects of dimethyl fumarate on experimental autoimmune myocarditis. in Archives of Medical Research
Elsevier Science Inc, New York., 39(7), 639-646.
https://doi.org/10.1016/j.arcmed.2008.07.003

Milenković M, Arsenović-Ranin N, Božić D, Bufan B, Jančić I, Stojić-Vukanić Z. Beneficial effects of dimethyl fumarate on experimental autoimmune myocarditis. in Archives of Medical Research. 2008;39(7):639-646.
doi:10.1016/j.arcmed.2008.07.003 .

Milenković, Marina, Arsenović-Ranin, Nevena, Božić, Dragana, Bufan, Biljana, Jančić, Ivan, Stojić-Vukanić, Zorica, "Beneficial effects of dimethyl fumarate on experimental autoimmune myocarditis" in Archives of Medical Research, 39, no. 7 (2008):639-646,
https://doi.org/10.1016/j.arcmed.2008.07.003 . .